Progress: Procedure completed
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | ENVI | ||
Former Responsible Committee | ENVI | ||
Committee Opinion | ITRE | SARTORI Amalia ( PPE) | |
Committee Opinion | IMCO | BASTOS Regina ( PPE) | |
Former Committee Opinion | IMCO | Ashley FOX ( ECR), Matteo SALVINI ( ENF) | |
Former Committee Opinion | ITRE | Vicky FORD ( ECR) |
Lead committee dossier:
Legal Basis:
TFEU 114-p1, TFEU 168-p4
Legal Basis:
TFEU 114-p1, TFEU 168-p4Subjects
Events
The Commission adopted a report on the Member States’ transposition of Article 118a of Directive 2001/83/EC of the European Parliament and the Council of 6 November 2001 on the Community code relating to medicinal products for human use as amended by Directive 2011/62/EU of the European Parliament and of the Council.
As a reminder, Directive 2011/62 / EU (Falsified Medicines Directive) was adopted to address growing concerns about the presence of falsified medicines in the legal supply chain . In 2014, falsified vials of Herceptin (trastuzumab), a cancer treatment, were discovered in several EU markets. Falsification also affects medicines for sexual dysfunction and hepatitis C.
The Falsified Medicines Directive introduces mandatory safety features on prescription medicines from February 2019 (unless explicitly exempted), and establishes an EU-wide logo to allow the identification of legal online retailers of medicines (applicable from 1 July 2015).
Article 118a of Directive 2001/83/EC requires Member States to lay down the rules on penalties applicable to infringements of the national provisions adopted pursuant to the Directive and to take all necessary measures to ensure that those penalties are implemented. The penalties must be effective, proportionate and dissuasive.
This report provides an overview of the Member States’ transposition measures and a qualitative assessment of their effectiveness. The Commission was aided in its assessment by the TRANSPOSE study conducted by an external contractor.
Transposition of Article 118a in Member States : the main conclusion of the report is that the transposition by Member States of Article 118a is satisfactory . A total of 26 Member States have introduced changes to their legislation in relation to penalties for the falsification of medicines, active substances and excipients in order to transpose Article 118a.
All 28 Member States apply criminal penalties in the form of imprisonment for the falsification of medicines. In 21 Member States, falsification per se is penalised, without the need to prove that the product is dangerous to health. For active substances, 23 Member States apply criminal penalties. For excipients, 14 Member States apply criminal penalties.
Where criminal penalties apply for the falsification of medicines, the maximum prison sentence is at least three years in 20 Member States . All Member States apply fines for the falsification of medicines.
Effectiveness : many of the national legal experts consulted as part of the TRANSPOSE study were unable to provide estimates of the effectiveness of specific penalties in relation to falsified medicines, active substances and excipients. Experts in 10 Member States considered that all of the penalties in place (criminal, civil and administrative) had at least some effect in reducing the presence of falsified medicines in the legal supply chain. Overall, administrative sanctions were rated as effective more often.
To further reinforce measures in place and strengthen their overall effectiveness, the report concludes that certain Member States could consider introducing additional criminal penalties or administrative sanctions in relation to falsified medicines, active substances or excipients.
Member States should ensure that adequate resources and personnel are allocated to enforcing penalties in place (e.g. by training new enforcement officers). Given the difficulties in obtaining accurate estimates of the extent of falsification in the EU market, the Commission considers that increased monitoring and data collection could allow for more accurate assessment of the effectiveness of specific national provisions.
Next steps : the Commission will continue to support Member States’ implementation of the Falsified Medicines Directive, in particular the medicine authentication system , which becomes applicable in the Member States in February 2019.
Furthermore, the EU logo for online pharmacies should ensure that consumers do not unknowingly buy medicines from illegal suppliers and should assist Member States in their enforcement efforts.
The report stresses the importance of continued cooperation , sharing of best practices and effective monitoring of the legislation in place to discourage the falsification of medicines through suitable penalties.
PURPOSE: to safeguard the functioning of the internal market for medicinal products, whilst ensuring a high level of protection of public health against falsified medicinal products.
LEGISLATIVE ACT: Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products.
CONTENT: following an agreement in first reading with the European Parliament, the Council adopted a directive aimed at preventing falsified medicines from entering the legal supply chain. The Directive acts against the increase of falsified medicines detected in the EU and the public health risk which that poses. The main provisions of the new Directive are as follows:
Safety features : medicinal products subject to prescription must bear safety features which should allow verification of the authenticity and identification of individual packs throughout the supply chain, and provide evidence of tampering. Non-prescription medicines are normally exempt from this obligation. In the light of a risk assessment, it will, however, be possible to extend the scope of safety features to non-prescription medicines for which this turns out to be necessary and to exclude certain prescription medicinal products from the obligation to bear safety features. Re-packaging of medicinal products remains possible, but the safety features must be replaced by equivalent safety features.
Good manufacturing practice : the manufacture of active substances intended for use in medicinal products must follow good manufacturing practice regardless of whether these ingredients are manufactured in the EU or imported. In the case of manufacture in third countries of active substances which are intended for export to the European Union, the competent authority of the exporting third country must certify that the manufacturing plant concerned is subject to regular, strict and transparent controls so as to ensure a protection of public health at least equivalent to that in the Union.
Obligations of importers, manufacturers and distributors : in order to strengthen the protection of the legal supply chain, importers, manufacturers and distributors of active substances must be registered with the competent authority as well as must brokers of medicinal products.
Furthermore, the manufacturers of medicinal products must verify that the manufacturer and the distributor of the respective active substances comply with good manufacturing practice and good distribution practices. They must also ensure that the excipients used are suitable for use in medicinal products. Wholesale distributors must verify that their supplying wholesale distributors are authorised.
Obligation to inform competent authorities about suspect products : manufacturers will be obliged to inform competent authorities about medicinal products they suspect of being falsified. A legal basis is created for customs authorities in co-operation with competent authorities, to take measures aiming to prevent that medicinal products suspected of being falsified enter into circulation.
Inspections : the competent authority of the Member State concerned shall, in cooperation with the Agency, ensure that the legal requirements governing medicinal products are complied with, by means of inspections, if necessary unannounced. Manufacturers, located in the Union or in third countries, and wholesale distributors of medicinal products shall be subject to repeated inspections.
Recall of dangerous products : Member States shall have a system in place which aims at preventing medicinal products that are suspected to be dangerous from reaching the patient. The system shall also allow recalls from patients, who received them, where necessary with the assistance of health professionals. If the medicinal product in question is suspected of presenting a serious risk to public health, the competent authority of the Member State in which the product was first identified, shall without any delay transmit a rapid alert notification to all Member States and all actors in the supply chain in that Member State. In the event of such medicinal products being deemed to have reached patients, urgent public announcements shall be issued within 24 hours in order to recall those medicinal products from the patients.
Distance selling to the public : the new directive also contains provisions aimed at protection patients from receiving falsified medicines through the sale of medicines via the internet. Websites offering medicines must be linked to the website of the respective competent authority on which a list of all persons or bodies in that Member State that are authorised to offer medicinal products for sale via internet must be available. Furthermore, such web pages must, in order to facilitate identification, display a common logo. These new provisions are without prejudice to Member States' right to regulate retail sales of medicinal products.
Public awareness : the Commission shall, in cooperation with the Agency and the competent authorities of the Member State, conduct or promote information campaigns aimed at the general public on the dangers of falsified medicinal products.
Sanctions: Member States must impose effective penalties inter alia for the manufacturing, distribution, import and export of falsified medicinal products.
ENTRY INTO FORCE: 21/07/2011.
TRANSPOSITION: 02/01/2013.
DELEGATED ACTS: the Commission is empowered to adopt delegated acts in accordance with Article 290 TFEU which concern good manufacturing and distribution practices for active substances, detailed rules for medicinal products introduced into the Union without being imported and safety features.
The European Parliament adopted by 569 votes to 12, with 7 abstentions, a legislative resolution on the proposal for a directive of the European Parliament and of the Council amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of medicinal products which are falsified in relation to their identity, history or source.
Parliament adopted its position at first reading under the ordinary legislative procedure. The amendments adopted in plenary are the result of a compromise reached between the European Parliament and the Council. They amend the Commission’s position as follows:
Definitions : the amended text stipulates that a definition of ‘falsified medicinal product’ should be introduced in order to clearly distinguish falsified medicinal products from other illegal products, as well as from infringements of intellectual property rights. Furthermore, products with unintentional quality defects resulting from manufacturing or distribution errors should not be confused with falsified medicinal products. To ensure uniform application of this Directive, the terms ‘active substance’ and ‘excipient’ should also be defined.
Application of the legislation : persons procuring, holding, storing, supplying or exporting medicinal products are only entitled to pursue their activities if they meet the requirements for obtaining a wholesale distribution authorisation in accordance with Directive 2001/83/EC. Given that the current distribution network for medicinal products is increasingly complex, the new legislation shall address all actors in the supply chain : this includes not only wholesale distributors, but also brokers who are involved in the sale or purchase of medicinal products without selling or purchasing those products themselves, and without owning and physically handling the medicinal products.
Obligations of the holder of the manufacturing authorisation : the holder of the manufacturing authorisation shall ensure that the excipients are suitable for use in medicinal products by verifying the appropriate good manufacturing practice on the basis of a formalised risk assessment. In this risk assessment, the holder of the manufacturing authorisation shall take into account the source and intended use of the excipients and previous incidents. The holder shall also, inter alia:
inform the competent authority and the marketing authorisation holder immediately if he obtains information that medicinal products which come under the scope of his manufacturing authorisation are, or are suspected of being, falsified irrespective of whether those products were distributed in the legal supply chain or by illegal means, including sold illegally by way of information society services; verify that the manufacturers, importers or distributors from whom they obtain active substances are registered with the competent authority of the Member State in which they are established; verify the authenticity and quality of the active substances and the excipients.
Imports, third countries : Member States shall take appropriate measures to ensure that the manufacture, import and distribution on their territory of active substances, including active substances that are intended for export, comply with good manufacturing practice and good distribution practices for active substances.
Active substances shall only be imported if the active substances have been manufactured in accordance with standards of good manufacturing practice at least equivalent to those laid down by EU legislation. The active substances are accompanied by a written confirmation from the competent authority of the exporting third country of the following: (i) the standards of good manufacturing practice applicable to the plant manufacturing the exported active substance are at least equivalent to those laid down by the Union; (ii) the plant concerned is subject to regular, strict and transparent controls and to the efficient enforcement of good manufacturing practice, including repeated and unannounced inspections, ensuring a protection of public health at least equivalent to that in the Union. In the event of findings relating to non-compliance, that information is supplied by the exporting third country to the Union without any delay.
It should be noted that the requirements on information shall apply to the supply of medicinal products to persons in third countries authorised or entitled to supply medicinal products to the public.
Safety features : safety features should allow verification of the authenticity and identification of individual packs, and provide evidence of tampering. The safety features shall not be partly or fully removed or covered , unless certain conditions are fulfilled. In particular, the safety features should be replaced in the case of re-packaging by equivalent safety features. To this end, the meaning of the term ‘equivalent’ should be clearly specified. Those strict conditions should provide adequate safeguards against falsified medicinal products entering the distribution chain, in order to protect patients, as well as the interests of marketing authorisation holders and manufacturers.
Medicinal products subject to prescription should as a general rule bear the safety feature. However, in view of the risk of medicinal products or categories of medicinal products there should be the possibility to exclude certain medicinal products or categories of medicinal products subject to prescription from the scope by way of a delegated act, following a risk assessment. Safety features should not be introduced for medicinal products or categories of medicinal products not subject to medical prescription unless, by way of exception, an assessment shows the risk of falsification, which leads to serious consequences. Those medicinal products should accordingly be listed in a delegated act.
Inspections : the competent authority of the Member State concerned shall, in cooperation with the Agency, ensure that the legal requirements governing medicinal products are complied with, by means of inspections, if necessary unannounced. Manufacturers, located in the Union or in third countries, and wholesale distributors of medicinal products shall be subject to repeated inspections.
Sales at a distance to the public : the illegal sale of medicinal products to the public via the Internet is an important threat to public health as falsified medicinal products may reach the public through such sale. This Directive should address this threat. In doing so, account should be taken of the fact that specific conditions for retail supply of medicinal products to the public have not been harmonised at Union level and, therefore, Member States may impose conditions for supplying medicinal products to the public within the limits of the Treaty on the Functioning of the European Union (TFEU).
The natural or legal person or the body provided for by national law offering medicinal products for sale at a distance is authorised or entitled to supply medicinal products to the public, also at a distance, in accordance with national legislation of the Member State in which that person or body is established. The authorised person or body shall communicate the following to the Member States: name or corporate name and permanent address of the place of activity from where the medicinal products are supplied; the starting date of the activity of offering medicinal products for sale at a distance by way of information society services; the address of the website used for that purpose and all relevant information necessary to identify that website.
Internet pharmacy sites will be required to display a common logo , which should be recognisable throughout the EU, so as to help the public to ascertain that they are linked to an authorised pharmacy. All authorised internet pharmacies will be linked to a central website in each Member State and will be listed on that website. The various national web sites will in turn be linked to an EU website . Citizens will also have to been informed about the risks involved in buying medicines via the internet.
The Agency´s website shall explicitly mention that the Member States´ websites contain information on persons or bodies authorised or entitled to supply medicinal products to the public and entitled to offer them for sale at a distance by way of information society services in the respective Member State.
Public awareness : the Commission shall, in cooperation with the Agency and the competent authorities of the Member State, conduct or promote information campaigns aimed at the general public on the dangers of falsified medicinal products. Those campaigns shall raise consumer awareness of the risks related to medicinal products supplied illegally to the public via the Internet and the function of the common logo, the Member States´ websites and the Agency´s website
Preventing dangerous medicines from reaching the patient : Member States shall have a system in place which aims at preventing medicinal products that are suspected to be dangerous from reaching the patient. With this aim the system shall cover the receipt and handling of notifications of suspected falsified medicinal products as well as of suspected quality defects of medicinal products and cover recalls by marketing authorisation holders or ordered by national competent authorities from all relevant actors in the supply chain both during and outside normal working hours. The system shall also allow recalls from patients, who received them, where necessary with the assistance of health professionals.
If the medicinal product in question is suspected of presenting a serious risk to public health, the competent authority of the Member State in which the product was first identified, shall without any delay transmit a rapid alert notification to all Member States and all actors in the supply chain in that Member State. In the event of such medicinal products being deemed to have reached patients, urgent public announcements shall be issued within 24 hours in order to recall those medicinal products from the patients.
International cooperation : the Commission and the Member States should cooperate closely and support ongoing work in international fora on this subject, such as the Council of Europe, Europol and the United Nations. In addition, the Commission, working closely with Member States, should cooperate with the competent authorities of third countries with a view to effectively combating the commercialisation of falsified medicinal products at a global level.
Penalties : the new Directive lays down penalties applicable to infringements of the national provisions. Those penalties shall not be inferior to those applicable to infringements of national law of similar nature and importance.
Delegated acts : the Commission should be empowered to adopt delegated acts in accordance with Article 290 TFEU which concern: (i) good manufacturing and distribution practices for active substances; (ii) detailed rules for medicinal products introduced into the Union without being imported and (iii) concerning safety features.
Implementing powers should be conferred on the Commission as regards the adoption of measures for the assessment of the regulatory framework applicable to the manufacturing of active substances exported from third countries to the Union and as regards a common logo that identifies websites which are legally offering medicinal products for sale at a distance to the public.
The Council took note of a presidency progress report on the state of play in the negotiations on the prevention of falsified medicines from entering into the legal supply chain of medicinal products ( doc. 10469/10 ).
The presidency also provided the Council with oral information on the progress in the discussions on the strengthening of the current pharmacovigilance system (aimed at protecting patients from adverse reactions to medicinal products). With regard to the pharmacovigilance part of the pharmaceutical package, the presidency will endeavour to reach an agreement at first reading with the European Parliament before the end of June.
The Committee on environment, public health and food safety adopted the report by Marisa MATIAS (GUE/NGL, PT) on the proposal for a directive of the European Parliament and of the Council amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of medicinal products which are falsified in relation to their identity, history or source.
It recommended that the European Parliament’s position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure) should be to amend the Commission proposal as follows:
Definitions and responsibilities: Members want to establish precise and clear definitions on not only the scope but also on the different actions in the supply chain and their responsibilities. With this in mind, they introduced definitions for “falsified medicinal products”, “active substance used as starting material” and “excipient”.
The amended text also introduces a distinction, in the definitions, between traders and brokers. For the system to be able to effectively protect public health, it is essential for the responsibilities of the various stakeholders to be clearly identified and for all stakeholders to be subject to a rigorous accreditation, verification and good-practice system. This must apply to parallel traders as well.
Excipients : falsified excipients can also present a serious risk for health and must also be included within the scope of the directive under examination. Both excipients and active pharmaceutical ingredients should be subject to relevant good manufacturing practices developed at the European level taking into account their own specificities.
Obligations of the holder of the manufacturing authorisation: Members consider that it is necessary to require the holder of the manufacturing authorisation to i) inform the competent authorities of products he gets knowledge of which are or which are reliably suspected to be falsified in relation to the identity, history or source of products manufactured by him in the legal or illegal supply chain, including on the internet; ii) verify the authenticity and quality of the active substances and the excipients.'
The Commission shall submit every year to the European Parliament and to the Council a report with reliable and accurate data on the current situation and trends in the falsification of medicinal products. The report shall, as a minimum, include where, how and by whom the falsified products were detected, their origin, and an exact description of the nature of the falsification. That report shall clearly distinguish falsified medicinal products from patent infringements.
Third countries: Members consider that the protection offered in third countries should be at least equivalent to that in the Community. In the event of non-compliance, this information should be immediately supplied by the exporting third country to the Community.
Other means of preventing counterfeiting: the Commission shall study the possibilities for the authentication of individual dosage forms, as a method of detecting falsified medicinal products.
Safety features: t he safety features should guarantee the identification, authenticity and uninterrupted traceability of the medicinal product from the factory to the consumer. The identification, authenticity and traceability of medicinal products must be guaranteed in all circumstances. Furthermore, the additional costs should be as low as possible.
Where original safety features have been removed and replaced , Members consider that patients and other actors in the supply chain must be explicitly informed via a label on the pack.
Safety features shall be considered equivalent where they comply with the harmonised measures provided for in the Directive, which shall ensure that they are equally efficient in identifying, authenticating, tracing and preventing tampering with medicinal products, and that they are equally technically difficult to duplicate.
According to Members, the performance criteria for the safety features can be waived for certain generic medicinal products or product categories
The decision the advisability of extending the safety features to other categories of medicinal products not subject to medical prescription will depend on an assessment carried out by the Commission no later than four years following the entry into force of this Directive.
Data protection: the measures contained in this Directive shall comply with the relevant provisions of Union law with regard to the protection of personal data.
Member States shall ensure that no collection or commercial processing of data takes place that would enable a link to be made between the medicinal products provided and the corresponding patients and shall ensure that the confidentiality of data generated by the use of safety features to authenticate medicinal products is safeguarded.
Internet sales: given that the internet is one of the main routes by which falsified medicinal products enter the European market, Members suggest that a distinction should be made between legitimate mail order or internet pharmacies and the illegal supply chain through non-controlled internet purchasing.
Internet pharmacies should, in Member States in which they are allowed to operate, require a special authorisation by the competent authority. The Commission shall adopt an EU logo for the front page of internet pharmacy sites, helping the public to identify whether a website offering to sell medicinal products is connected to an authorised pharmacy. The logo shall be linked to a central website at Member State level, to be established by the Member State, that allows the visitor to check the authenticity of the logo and that provides background information on the risks related to buying medicinal products on the internet.
Member States shall take the appropriate measures to ensure that all authorised pharmacy internet sites linked to pharmacies within their territory display the EU logo.
Member States shall also ensure that i) the internet is continuously monitored with regard to the selling of medicinal products; ii) all legitimate mail-order pharmacies operating in the internal market adhere to professional standards and guidance for internet pharmacy services, including a specific code of ethics .
Public awareness: Members call on the Commission, in cooperation with the European Medicines Agency (the ‘Agency’) and Member State authorities, to launch campaigns informing and raising awareness among consumers of the risk involved in purchasing falsified medicinal products.
Inspections: in order to guarantee the safety of medicinal products, Members consider it vital to strengthen and extend the system of inspections. In this regard, it will be necessary to take into account all the actors throughout the supply chain and not simply the wholesale distributors.
Exports: the Directive should also seek to reduce the wholesale distribution of falsified medicines towards third countries. Members consider that applying less stringent rules to exports or products in transit to third countries would damage the Community’s credibility in its insistence on strengthening international cooperation in the combat against falsified medicines. This is why the report calls on the Member States to take all necessary measures to ensure that no falsified medicines are distributed or exported from their territory to third countries .
Sanctions: Members propose further strengthening the measures proposed by the Commission. They stress that the falsification of medicines is a serious criminal activity, which places human lives in danger and that appropriate sanctions are required. The threat that falsified or counterfeit medicines represent to human health needs to be taken into account when drawing up rules on the sanctions to be applied. These sanctions need to be equivalent to those typically applied for illegal acts related to narcotics .
Exchange of information and reports: Members call on the Commission to create a network between it, the Agency and the Member States’ competent authorities and involve patients' and consumers' organisations to ensure the exchange of information on the measures taken to combat the falsification of medicinal products, including on the penalties systems in place. This network shall aim at defining best practices and shall contribute to increased cooperation in the area of prevention and enforcement. The Commission, the Agency and the competent authorities in the Member States shall report annually to this network on the actions they have undertaken.
International cooperation: the European Union should support the drafting of an international agreement increasing the penalties for falsifying medicinal products, and of an additional protocol to the United Nations Convention against Transnational Organised Crime (Palermo convention). In addition, the Commission and the Member States should cooperate closely with the Council of Europeon the establishment of a European Convention on the suppression of the falsification of medicinal products and trafficking in falsified medicinal products.
Lastly, many amendments adopted by Members seek to replace the “old comitology procedure” by the new procedure foreseen in Article 290 of the Treaty on the Functioning of the European Union (delegated acts).
On the basis of progress reports, the Presidency informed the Council of the state of play in the negotiations on two parts of the "pharmaceutical package": preventing falsified medicines from entering into the legal supply chain of medicinal products and the strengthening and rationalising of the current pharmacovigilance system.
Under the Swedish Presidency, the preparatory bodies of the Council pursued their work with high priority on these two parts of the package.
1) Concerning the draft directive on preventing the entry into the legal supply chain of falsified medicinal products , the working group reached tentative agreement on a number of technical aspects, including:
· the definition of "falsified medicinal products";
· the proposed definition of ''trading of medicinal products'' has been changed to ''brokering of medicinal products'' and amended, thereby clarifying which actors in the supply chain should be subject to the responsibilities of brokers. The proposed introduction of obligations for brokers aim to reinforce the traceability of medicinal products;
· a clarification of the relationship between the proposed new provisions in Directive 2001/83/EC and Community legislation on intellectual property rights.
Other elements of the proposal still need further discussion, notably with regard to the strengthening of controls of non active substances used in pharmaceuticals (excipients) and the proposed safety features aiming to render falsification more difficult.
The proposal includes provisions requiring the accreditation of third party auditors of Good Manufacturing Practices and Good Distribution Practices. A majority of delegations object to accreditation, since they maintain that such a system could result in a transfer of responsibility from manufacturers and importers as well as make enforcement by national competent authorities more difficult. The Presidency has therefore proposed to delete the provisions regarding accreditation from the text. Some delegations have expressed an interest in the possibility of establishing third party accreditation at a national level.
2) Concerning the proposals for a regulation and a directive on strengthening the EU system for the safety monitoring of medicinal products ("pharmacovigilance"), the working group reached tentative agreement on a number of questions including:
· a clarification of the relation between the proposed new provisions in Directive 2001/83/EC and Regulation (EC) 726/2004 on the one hand and the Community legislation on protection of personal data on the other hand;
· a strengthening of the role of the Pharmacovigilance Risk Assessment Committee (PRAC) in relation to the Committee for Medicinal Products for Human Use and to the Coordination Group set up by Article 27 of Directive 2001/83/EC (CMD), including an obligation for these last two bodies to explain any differences in opinion compared to the PRAC;
· a change in the composition of the PRAC and in the method for nominating the PRAC members so that all Member States will be represented;
· the inclusion of a requirement for the Agency, in collaboration with the Member States and the Commission, to draw up functional specifications for the Eudravigilance database which will take account of the role and experience of national competent authorities for pharmacovigilance. The new reporting obligations to Eudravigilance will not apply until these specifications are met and to this end a transitional period is envisaged;
· the legal status of CMD opinions and how they are implemented in Member States. Here, text redrafting proposals are under legal scrutiny.
The Working Party has continued to discuss other central provisions of the proposals, mainly in relation to the Community Procedure and Referrals, the Recording and Reporting of adverse reactions, the Periodic Safety Update Reports and the Post Authorisation Safety Studies.
A number of issues still require further examination, such as the recording and reporting of adverse reactions and the proposed list of medicinal products for human use under intensive monitoring.
At this stage, all delegations have a general scrutiny reservation on the entire proposal while the Danish, Maltese and United Kingdom delegations have parliamentary scrutiny reservations.
3) With regard to the third part of the "pharmaceutical package", the proposals for a regulation and a directive concerning information for the general public on medicinal products, the Presidency recalled the strong concerns of many Member States. The Commission made it clear that it is prepared to show flexibility in order to find a common basis for the future negotiations.
PURPOSE: to prevent the entry into the legal supply chain of medicinal products which are falsified.
PROPOSED ACT: Directive of the European Parliament and of the Council.
BACKGROUND: there is an alarming increase in the EU of medicinal products which are falsified in relation to their identity, history or source. These products are, from the point of view of EU pharmaceutical legislation, illegal insofar as they do not comply with the Community rules for medicinal products. Moreover, the number of falsifications of innovative and life-saving medicines is increasing. In this way, in 2007, many thousand packs of falsified life-saving drugs reached patients in the EU.
The underlying causes for falsified medicinal products remaining undetected in the legal supply chain are manifold, but can be reduced to four aspects: (i) falsified medicinal products can not always be easily distinguished from originals; (ii) the distribution chain has become very complex and is only as strong as its weakest link; (iii) there are legal uncertainties as to the regime applicable to products introduced into the EU while allegedly not being placed on the market; (iv) lastly, already the active pharmaceutical ingredients (API) entering the manufacturing process may be a falsification of the original API.
The existing provisions of Directive 2001/83/EC are in some respects insufficient to address these concrete causes. In view of the time span between the proposal for amendments to Directive 2001/83/EC and their effective implementation, there is a clear need for the Commission to act now.
CONTENT: in order to address the risk of falsified medicinal products entering the legal supply chain, the Commission proposes a number of amendments to Directive 2001/83/EC. These include:
certain obligations for stakeholders other than wholesale distributors, who are involved in the distribution chain. These stakeholders are typically involved in the transactions without actually handling the products (for example, by auctioning or brokering products); a legal basis for the Commission to render obligatory specific safety-features (such as a serial number or a seal) on the packaging of prescription-medicines; a prohibition in principle of manipulating (i.e. removing, tampering with, or over-labelling) safety features on the packaging by stakeholders situated “in-between” the original manufacturer and the last stakeholder in the distribution chain (typically the pharmacist) or end user (doctor/patient); compulsory audits of wholesale distributors of medicinal products in order to ensure reliability of business partners; strengthened requirements for imports of API from third countries if it could not be established that the regulatory framework in the respective third country ensures a sufficient level of protection of human health for products exported to the EU; audits of manufacturers of API; stricter rules for inspections including increased transparency of inspection results through publication in the EudraGMP database managed by the EMEA.
PURPOSE: to prevent the entry into the legal supply chain of medicinal products which are falsified.
PROPOSED ACT: Directive of the European Parliament and of the Council.
BACKGROUND: there is an alarming increase in the EU of medicinal products which are falsified in relation to their identity, history or source. These products are, from the point of view of EU pharmaceutical legislation, illegal insofar as they do not comply with the Community rules for medicinal products. Moreover, the number of falsifications of innovative and life-saving medicines is increasing. In this way, in 2007, many thousand packs of falsified life-saving drugs reached patients in the EU.
The underlying causes for falsified medicinal products remaining undetected in the legal supply chain are manifold, but can be reduced to four aspects: (i) falsified medicinal products can not always be easily distinguished from originals; (ii) the distribution chain has become very complex and is only as strong as its weakest link; (iii) there are legal uncertainties as to the regime applicable to products introduced into the EU while allegedly not being placed on the market; (iv) lastly, already the active pharmaceutical ingredients (API) entering the manufacturing process may be a falsification of the original API.
The existing provisions of Directive 2001/83/EC are in some respects insufficient to address these concrete causes. In view of the time span between the proposal for amendments to Directive 2001/83/EC and their effective implementation, there is a clear need for the Commission to act now.
CONTENT: in order to address the risk of falsified medicinal products entering the legal supply chain, the Commission proposes a number of amendments to Directive 2001/83/EC. These include:
certain obligations for stakeholders other than wholesale distributors, who are involved in the distribution chain. These stakeholders are typically involved in the transactions without actually handling the products (for example, by auctioning or brokering products); a legal basis for the Commission to render obligatory specific safety-features (such as a serial number or a seal) on the packaging of prescription-medicines; a prohibition in principle of manipulating (i.e. removing, tampering with, or over-labelling) safety features on the packaging by stakeholders situated “in-between” the original manufacturer and the last stakeholder in the distribution chain (typically the pharmacist) or end user (doctor/patient); compulsory audits of wholesale distributors of medicinal products in order to ensure reliability of business partners; strengthened requirements for imports of API from third countries if it could not be established that the regulatory framework in the respective third country ensures a sufficient level of protection of human health for products exported to the EU; audits of manufacturers of API; stricter rules for inspections including increased transparency of inspection results through publication in the EudraGMP database managed by the EMEA.
Documents
- Follow-up document: COM(2018)0049
- Follow-up document: EUR-Lex
- Final act published in Official Journal: Directive 2011/62
- Final act published in Official Journal: OJ L 174 01.07.2011, p. 0074
- Draft final act: 00003/2011/LEX
- Commission response to text adopted in plenary: SP(2011)2217
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament, 1st reading: T7-0056/2011
- Debate in Parliament: Debate in Parliament
- Debate in Council: 3019
- Committee report tabled for plenary, 1st reading/single reading: A7-0148/2010
- Committee report tabled for plenary, 1st reading: A7-0148/2010
- Committee opinion: PE438.139
- Committee opinion: PE430.741
- Amendments tabled in committee: PE439.406
- Amendments tabled in committee: PE439.407
- Amendments tabled in committee: PE439.409
- Amendments tabled in committee: PE439.860
- Committee draft report: PE430.883
- Debate in Council: 2980
- Economic and Social Committee: opinion, report: CES1191/2009
- Legislative proposal: COM(2008)0668
- Legislative proposal: EUR-Lex
- Document attached to the procedure: SEC(2008)2674
- Document attached to the procedure: EUR-Lex
- Document attached to the procedure: SEC(2008)2675
- Document attached to the procedure: EUR-Lex
- Legislative proposal published: COM(2008)0668
- Legislative proposal published: EUR-Lex
- Legislative proposal: COM(2008)0668 EUR-Lex
- Document attached to the procedure: SEC(2008)2674 EUR-Lex
- Document attached to the procedure: SEC(2008)2675 EUR-Lex
- Economic and Social Committee: opinion, report: CES1191/2009
- Committee draft report: PE430.883
- Amendments tabled in committee: PE439.406
- Amendments tabled in committee: PE439.407
- Amendments tabled in committee: PE439.409
- Amendments tabled in committee: PE439.860
- Committee opinion: PE430.741
- Committee opinion: PE438.139
- Committee report tabled for plenary, 1st reading/single reading: A7-0148/2010
- Commission response to text adopted in plenary: SP(2011)2217
- Draft final act: 00003/2011/LEX
- Follow-up document: COM(2018)0049 EUR-Lex
Activities
- Licia RONZULLI
Plenary Speeches (5)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Luís Paulo ALVES
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Laima Liucija ANDRIKIENĖ
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Zigmantas BALČYTIS
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Edite ESTRELA
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Diogo FEIO
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Juozas IMBRASAS
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Giovanni LA VIA
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- David MARTIN
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Louis MICHEL
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Andreas MÖLZER
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Alfredo PALLONE
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Maria do Céu PATRÃO NEVES
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Raül ROMEVA i RUEDA
Plenary Speeches (4)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Roberta ANGELILLI
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- George BECALI
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Sebastian Valentin BODU
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Viorica DĂNCILĂ
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Ilda FIGUEIREDO
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Bruno GOLLNISCH
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Andrzej GRZYB
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Jean-Luc MÉLENCHON
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Willy MEYER
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Miroslav MIKOLÁŠIK
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Alexander MIRSKY
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Rolandas PAKSAS
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Crescenzio RIVELLINI
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Thomas ULMER
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Anna ZÁBORSKÁ
Plenary Speeches (3)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Elena Oana ANTONESCU
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Alfredo ANTONIOZZI
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Regina BASTOS
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Falsified medicinal products (debate)
- Jean-Luc BENNAHMIAS
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Vito BONSIGNORE
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Nikolaos CHOUNTIS
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Philip CLAEYS
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Pat the Cope GALLAGHER
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Elisabetta GARDINI
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Falsified medicinal products (debate)
- Robert GOEBBELS
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Marian HARKIN
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Syed KAMALL
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Sergej KOZLÍK
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Petru Constantin LUHAN
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Clemente MASTELLA
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Cristiana MUSCARDINI
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Wojciech Michał OLEJNICZAK
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Franz OBERMAYR
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Siiri OVIIR
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Falsified medicinal products (debate)
- Oreste ROSSI
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Falsified medicinal products (debate)
- Daciana Octavia SÂRBU
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Czesław Adam SIEKIERSKI
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Bart STAES
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Derek VAUGHAN
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Diana WALLIS
Plenary Speeches (2)
- 2016/11/22 Falsified medicinal products (debate)
- 2016/11/22 Falsified medicinal products (debate)
- Åsa WESTLUND
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Falsified medicinal products (debate)
- Iva ZANICCHI
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Artur ZASADA
Plenary Speeches (2)
- 2016/11/22 Explanations of vote
- 2016/11/22 Explanations of vote
- Antonello ANTINORO
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Liam AYLWARD
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Paolo BARTOLOZZI
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Elena BĂSESCU
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Bas BELDER
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Jan BŘEZINA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Antonio CANCIAN
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Alain CADEC
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Silvia COSTA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- George Sabin CUTAȘ
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Francesco DE ANGELIS
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Anne DELVAUX
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Luigi Ciriaco DE MITA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Christine DE VEYRAC
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Isabelle DURANT
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Ioan ENCIU
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Göran FÄRM
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Lidia Joanna GERINGER DE OEDENBERG
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Ingeborg GRÄSSLE
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Louis GRECH
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Catherine GRÈZE
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Mathieu GROSCH
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Nathalie GRIESBECK
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Françoise GROSSETÊTE
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Anna HEDH
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Roger HELMER
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Jolanta Emilia HIBNER
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Salvatore IACOLINO
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Richard HOWITT
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Anneli JÄÄTTEENMÄKI
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Elisabeth JEGGLE
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Dennis de JONG
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Krišjānis KARIŅŠ
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Martin KASTLER
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Tunne KELAM
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Jürgen KLUTE
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Holger KRAHMER
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Constance LE GRIP
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Patrick LE HYARIC
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Olle LUDVIGSSON
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Astrid LULLING
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Monica MACOVEI
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Jiří MAŠTÁLKA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Barbara MATERA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Judith A. MERKIES
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Alajos MÉSZÁROS
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Claudio MORGANTI
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Miroslav OUZKÝ
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Pier Antonio PANZERI
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Georgios PAPANIKOLAOU
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Antonyia PARVANOVA
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Gilles PARGNEAUX
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Jaroslav PAŠKA
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Miguel PORTAS
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Cristian Dan PREDA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Jens ROHDE
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Zuzana ROITHOVÁ
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Anna ROSBACH
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Dagmar ROTH-BEHRENDT
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Amalia SARTORI
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Vilja SAVISAAR-TOOMAST
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Horst SCHNELLHARDT
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Peter SKINNER
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Alyn SMITH
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Bogusław SONIK
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Struan STEVENSON
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Dimitar STOYANOV
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Catherine STIHLER
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Csanád SZEGEDI
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Hannu TAKKULA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Nuno TEIXEIRA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Silvia-Adriana ȚICĂU
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Georgios TOUSSAS
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Michail TREMOPOULOS
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
- Giommaria UGGIAS
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Marita ULVSKOG
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Jarosław WAŁĘSA
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Angelika WERTHMANN
Plenary Speeches (1)
- 2016/11/22 Explanations of vote
- Marina YANNAKOUDAKIS
Plenary Speeches (1)
- 2016/11/22 Falsified medicinal products (debate)
Amendments | Dossier |
443 |
2008/0261(COD)
2010/02/15
ITRE
73 amendments...
Amendment 100 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 a (new) (4a) For a transitional period of 3 years, safety features shall be regarded as equivalent if they make it equally possible to ascertain the identity, authenticity and uninterrupted traceability of the medicinal product, without its being necessary to open the immediate packaging, or they make it equally difficult to counterfeit the product. If a safety feature is removed, replaced or covered, this point should also be applicable to the new safety feature, provided that the primary safety feature is not hidden and cannot be recognised.
Amendment 101 #
Proposal for a directive – amending act Article 1 – paragraph 9 Directive 2001/83/EC Article 77 – paragraph 4 '4. The Member States shall forward to the Agency a copy of the authorization referred to in paragraph 1. The Agency shall enter that information in the Community database referred to in Article 111(6). At the request of the Commission or any Member State, Member States shall supply, within a reasonable period of time, all appropriate information concerning the individual authorization which they have granted under paragraph 1.'
Amendment 102 #
Proposal for a directive – amending act Article 1 – point 13 – point a Directive 2001/83/EC Article 80 – point e (e) they must keep records either in the form of purchase/sales invoices or on computer, or in any other form, giving for any transaction in medicinal products received, dispatched
Amendment 103 #
Proposal for a directive – amending act Article 1 – point 13 – point b a (new) Directive 2001/83/EC Article 80 – paragraph 1 – point j (new) (ba) the following point (j) shall be added: '(j) they must inform a medicinal product marketing authorisation holder, at the latter's request, about the orders they have received for medicinal products. The information pursuant to the first sentence must at the minimum include the name and address of the party placing the order and the particulars listed in point (e), first to fourth indents.'
Amendment 104 #
Proposal for a directive – amending act Article 1 – point 13 a (new) Directive 2001/83/EC Article 84 a (new) (13a) the following Article 84a is inserted after Article 84. Article 84a The Commission shall publish guidelines on specific good manufacturing practices for active pharmaceutical ingredients and specific good manufacturing practices for Excipients. To this end, it shall consult the Committee for Proprietary Medicinal Products established under Council Directive 75/319/EEC and the Pharmaceutical Committee established by Council Decision 75/320/EEC.
Amendment 105 #
Proposal for a directive – amending act Article 1 – point 14 Directive 2001/83/EC Article 85b Persons trading or brokering medicinal products shall ensure that the traded or brokered medicinal products are covered by a marketing authorization granted pursuant to Regulation (EC) No 726/2004 or by the competent authorities of a Member State in accordance with this Directive.
Amendment 106 #
Proposal for a directive – amending act Article 1 – point 14 Directive 2001/83/EC Article 85b – paragraph 1 Persons trading or brokering medicinal products shall ensure that the traded or brokered medicinal products
Amendment 107 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Title VII a (new) – Article 85 c (new) Amendment 108 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Article 88 – paragraph 1 a (new) 14a) In Article 88, the following paragraph 1a is inserted after paragraph 1: '1a. Member States, in cooperation with the Commission and after consulting interested parties, shall devise an information strategy concerning the reliability of suppliers of pharmaceuticals. This strategy should take into account the various national legislations regulating the supply of pharmaceuticals and the risk attendant upon certain methods of supply of pharmaceuticals, such as illegal Internet channels.'
Amendment 109 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Article 88 b (new) Article 88b Member States, in cooperation with the Commission and after consultation with representatives of stakeholders, shall devise an information strategy relating to the safety of consignments of medicinal products. The strategy shall take account of the various national legal provisions concerning the supply of medicinal products and the risks associated with certain types of supply of medicinal products and with illegal trading on the Internet.
Amendment 110 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Article 97 – paragraph 5 a (new) (14a) In Article 97, the following paragraph 5a is added: 5a. The Commission shall ensure, in cooperation with the Agency and national authorities, that manufacturers, importers, wholesale distributors, traders and brokers, either collectively or individually, promote public information campaigns in the various media (press, television, radio, Internet) to raise awareness of the risks connected with the purchase of falsified medicinal products on the Internet.
Amendment 111 #
Proposal for a directive – amending act Article 1 – point 16 Directive 2001/83/EC Article 111 b – paragraph 2 2. The Commission, in accordance with the
Amendment 112 #
Proposal for a directive – amending act Article 1 – point 15 – point c Directive 2001/83/EC Article 111 – paragraph 7 7. If the outcome of the inspection as referred to in paragraph 1 is that the person does not comply with the principles and guidelines of good manufacturing practices or good distribution practices as provided for by Community legislation, the information shall be entered in the Community database referred to in paragraph 6 and the manufacturing and distribution processes must cease forthwith.'
Amendment 113 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118 c a (new) Article 118ca The Commission and the Member States shall cooperate closely with the Council of Europe on the establishment of a European Convention on the suppression of the falsification of medicinal products and trafficking in falsified medicines. The Convention covers the civil and criminal law aspects of falsification and trafficking of falsified medicinal products.
Amendment 114 #
Proposal for a directive – amending act Article 2 – paragraph 1 (1) Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by [insert concrete date
Amendment 42 #
Proposal for a directive – amending act Citation 1 Having regard to the Treaty
Amendment 43 #
Proposal for a directive – amending act Recital 4 b (new) (4b) The new draft Convention of the Council of Europe on counterfeiting of medicinal products and similar crimes involving threats to public health, which is expected to be open for signature in 2010, should be supported by the Commission and the Member States.
Amendment 44 #
Proposal for a directive – amending act Recital 4 c (new) (4c) A considerable number of medicines purchased over the internet come from sites that conceal their actual physical address. Therefore, a distinction should be made between legitimate mail-order or internet pharmacies and the illegal supply chain through non-controlled internet purchasing. Member States should ensure that the internet sale of medicinal products is continuously monitored by designated bodies.
Amendment 45 #
Proposal for a directive – amending act Recital 4 d (new) (4d) European citizens should be made aware of the danger to their health from ordering products from non-controlled internet websites or from the illegal supply chain. The Commission together with the Member States and in cooperation with the patients' and consumers' organisations should adopt measures to increase awareness among the general public on the risks related to purchasing medicinal products on the internet. Public awareness campaigns should inform citizens whether their internet pharmacy is officially registered and controlled by public authorities.
Amendment 46 #
Proposal for a directive – amending act Recital 4 e (new) Amendment 47 #
Proposal for a directive – amending act Recital 6 a (new) (6a) Counterfeit medicinal products are often found to have been supplied in response to orders placed over the Internet. In accordance with the provisions of the Treaty, particularly Article 168 of the TFEU, Member States are responsible for regulating the marketing of medicinal products at the last level of trade, particularly in pharmacies. This also includes regulating the marketing of medicinal products by mail order and over the Internet. The case law of the Court of Justice permits Member States to impose an absolute ban on the supply of prescription medicines by mail order, in accordance with the wide margin of discretion which they enjoy on account of the dangers associated with this method of marketing.
Amendment 48 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of
Amendment 49 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of
Amendment 50 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, together with interested parties, should be free to determine the particular aspects of technologies for combating counterfeiting of pharmaceuticals which they consider most appropriate for their pharmaceutical distribution systems, taking account of the authentication seal adopted by this Directive.
Amendment 51 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, in cooperation with stakeholders, should be permitted to regulate the particular aspects of authentication of medicines in the way which they consider most appropriate for their market in medicinal products, taking account of the safety features established in accordance with this Directive.
Amendment 52 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, working together with stakeholders, should be free to determine the particular aspects of medicines authentication which they believe are most appropriate for their medicine distribution system, taking into account the safety features adopted pursuant to this Directive.
Amendment 53 #
Proposal for a directive – amending act Recital 7 b (new) (7b) Technologies which make it possible to identify and trace pharmaceuticals at the individual dose level may be a means of combating counterfeiting of medicinal products more effectively and deserve careful analysis by the institutions responsible for safeguarding public health in Europe.
Amendment 54 #
Proposal for a directive – amending act Recital 7 b (new) (7b) In order to provide patients with timely protection from the risks of falsified medicinal products, a manufacturing authorisation holder who partly or fully removes or covers-up safety features that are applied on a voluntary basis should be required to replace such safety features with equivalent safety features designed to ensure the identification, authentication and traceability of prescription medicinal products as soon as this Directive enters into force.
Amendment 55 #
Proposal for a directive – amending act Recital 7 c (new) (7c) The use of technologies that allow the authentication and tracing of medicinal products at the level of individual dosage forms (e.g. the capsule, tablet or tamper- evident immediate packaging of liquids) can also be very valuable in allowing better monitoring of products on the market.
Amendment 56 #
Proposal for a directive – amending act Recital 8 (8) Any actor in the supply chain who
Amendment 57 #
Proposal for a directive – amending act Recital 10 (10) In order to increase reliability in the distribution chain, wholesale distributors should verify, either by themselves or through a body accredited for that purpose,
Amendment 58 #
Proposal for a directive – amending act Recital 11 a (new) (11a) European citizens should have their attention drawn to the risks which arise when medicinal products are ordered from illegal suppliers. In particular, public information measures should be promoted in the Member States and throughout Europe. The Commission and Member States should adopt measures to increase awareness among the general public of the risks related to purchasing medicinal products on the Internet.
Amendment 59 #
Proposal for a directive – amending act Recital 11 a (new) (11a) In particular, information campaigns should be promoted at both national and European level. The Commission and Member States should adopt effective measures to improve public awareness of the risks arising from purchases of pharmaceuticals over the Internet.
Amendment 60 #
Proposal for a directive – amending act Recital 13 (13) The manufacture of active pharmaceutical ingredients or excipients should be subject to the relevant good manufacturing practices in force within the Community irrespective of whether those ingredients were manufactured in the Community or imported. With regard to the manufacture of active pharmaceutical ingredients in third countries, it should be ensured that the rules for the manufacture of active pharmaceutical ingredients intended for export to the Community, including inspection and enforcement, provide for a
Amendment 61 #
Proposal for a directive – amending act Recital 13 a (new) (13a) Pharmaceutical excipients, other than active pharmaceutical ingredients, used in drug product manufacturing should be subject to appropriate controls by the manufacturing authorisation holder such that the excipients are checked and verified by the manufacturing authorisation holder to be suitable for use in the production of drug products in accordance with good manufacturing practices and that the verification provides for an adequate level of protection of public health.
Amendment 62 #
Proposal for a directive – amending act Recital 17 a (new) (17a) In order to identify each individual package of medicinal products subject to medical prescription other than radiopharmaceuticals, certain product characteristics (i.e. product code, expiry date, lot number) should appear amongst the safety features. This information should be available in a machine-readable format which is harmonised across Europe using an international coding standard.
Amendment 63 #
Proposal for a directive – amending act Recital 18 a (new) (18a) The Member States should cooperate to enforce existing restrictions on illegal trading in medicinal products over the Internet, including by means of Europol.
Amendment 64 #
Proposal for a directive – amending act Recital 18 a (new) (18a) Member States should cooperate, including with Europol, to step up the existing restrictions on the illegal supply of pharmaceuticals over the Internet.
Amendment 65 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a (new) Amendment 66 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2a (new) (-1) In Article 1, the following point 2a is inserted after point 2: ‘2a. Falsified medicinal product means any medicinal product which has been deliberately falsified with regard to its: (a) properties, including packaging, labelling, designation and formulation, as regards both the active pharmaceutical ingredients and their dosage; (b) production, including the manufacturer, the country of manufacture, the country of origin and the marketing authorisation holder; (c) its origin, including the records and documents relating to identification of the distribution chain. The Commission shall adapt this definition in accordance both with technical and scientific progress and with international agreements. This definition shall not concern violations of the legislation on industrial property rights. This definition shall not include production faults.'
Amendment 67 #
Proposal for a directive – amending act Article 1 – point -1 a (new) Directive 2001/83/EC Article 1 – point 3 a (new) (-1a) In Article 1, the following point 3a is inserted after point 3: (3a) Excipient: “Excipients are the constituents of a pharmaceutical form apart from the active substance. Excipients include, for example, fillers, disintegrants, lubricants, colouring matters, antioxidants, preservatives, adjuvants, stabilisers, thickeners, emulsifiers, solubilisers, permeation enhancers, flavouring and aromatic substances, as well as the constituents of the outer covering of the medicinal products, for example gelatine capsules.”
Amendment 68 #
Proposal for a directive – amending act Article 1 – point -1 b (new) Directive 2001/83/EC Article 1 – point 5 a (new) (-1b) In Article 1, the following point 5a is inserted after point 5: '(5a) Falsified medicinal product: Any medicinal product that has been deliberately falsified in relation to its: (a) identity, including its packaging, labelling, name or composition in terms of both ingredients, including exipients and active ingredients, or the dosage thereof; (b) source, including the manufacturer, the country of manufacture, the country of origin or the marketing authorisation holder; (c) history, including the registers or documents enabling the distribution chain to be identified. The Commission shall, in cooperation with the Agency and Member State authorities, update this definition on the basis of technical and scientific progress and international agreements. This definition is not related to infringements of legislation on intellectual and industrial property rights or patent rights. This definition does not include manufacturing errors.'
Amendment 69 #
Proposal for a directive – amending act Article 1 – point 1 Directive 2001/83/EC Article 1 – point 17 a All activities consisting of
Amendment 70 #
Proposal for a directive – amending act Article 1 – point 1 a (new) Directive 2001/83/EC Article 1 – point 17 b (new) (1a) In Article 1, the following point 17b is inserted after point 17a: '17b. Persons authorised to supply medicinal products means persons or rights-holders who possess a wholesale distribution authorisation for medicinal products, without detriment to persons or rights-holders who are exempt from the authorisation requirement.'
Amendment 71 #
Proposal for a directive – amending act Article 1 – point 1 a (new) Directive 2001/83/EC Article 1 – point 18 b (new) (1a) In Article 1, the following point 18b is inserted after point 18 a: 18b) Persons authorised to supply medicinal products: Persons or entities in the possession of a wholesale distribution authorisation without prejudice to persons or entities exempt from holding an authorisation to supply medicinal products.
Amendment 72 #
Proposal for a directive – amending act Article 1 – point 2 a (new) Directive 2001/83/EC Article 2 – paragraph 3 a (new) (2a) In Article 2, the following paragraph is inserted after paragraph 3: '3a. Nothing in this Directive shall affect the right of Member States to restrict or prohibit the sale of prescription medicines on the internet'.
Amendment 73 #
Proposal for a directive – amending act Article 1 – point 2 a (new) Directive 2001/83/EC Article 2 – paragraph 3 a (new) (2a) In Article 2, the following paragraph 3a is inserted after paragraph 3: '3a. The provisions of this Directive shall be without prejudice to the right of the Member States to restrict or prohibit trading in prescription medicinal products over the Internet.'
Amendment 74 #
Proposal for a directive – amending act Article 1 – point 2 a (new) Directive 2001/83/EC Article 2 – paragraph 3 a (new) 2a) In Article 2, the following paragraph 3a is inserted after paragraph 3: '3a. This Directive shall not in any way alter the right of the Member States to restrict or prohibit the sale of prescription pharmaceuticals over the Internet.'
Amendment 75 #
Proposal for a directive – amending act Article 1 – point 3 - point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 a (new) The manufacturing authorisation holder should ensure that starting materials other than active pharmaceutical ingredients are assessed as being suitable for use in pharmaceutical products. The manufacturing authorisation holder shall ensure that the process by which the assessment is achieved is described in a quality system which is available for inspection by competent authorities.
Amendment 76 #
Proposal for a directive – amending act Article 1 – point 3 - point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 a (new) Excipients shall be subject to their own good manufacturing practices developed by the Commission in accordance with Article 84 a.
Amendment 77 #
Proposal for a directive – amending act Article 1 – point 3 - point b Directive 2001/83/EC Article 46 – point g '(g) to inform the competent authority of products he gets knowledge of which are or which are reliably suspected to be falsified in relation to the identity, history or source of products manufactured by him.'
Amendment 78 #
Proposal for a directive – amending act Article 1 – point 3 - point b a (new) Directive 2001/83/EC Article 46 – point h (new) (ba) The following point (h) is added: ''(h) to make the importation of the active principles from third countries subject to specific and stringent monitoring, in order to check whether good manufacturing practices have been adhered to and the intrinsic quality of the active principles.'
Amendment 79 #
Proposal for a directive – amending act Article 1 – point 4 Directive 2001/83/EC Article 46 b – paragraph 2 – point b (b) they are accompanied by a written confirmation from the exporting third country that the standards of good manufacturing practice applicable to the plant manufacturing the exported active substance and the control mechanisms are at least equivalent to those laid down by the Community, and that the plant is subject to control and enforcement ensuring that those good manufacturing practices cannot be circumvented.
Amendment 80 #
Proposal for a directive – amending act Article 1 – point 5 Directive 2001/83/EC Article 47 – paragraph 2 a (new) Amendment 81 #
Proposal for a directive – amending act Article 1 – point 8 Directive 2001/83/EC Article 54 – point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products
Amendment 82 #
Proposal for a directive – amending act Article 1 – point 8 Directive 2001/83/EC Article 54 – point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products
Amendment 83 #
Proposal for a directive – amending act Article 1 – point 8 Directive 2001/83/EC Article 54 – point o '(o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products
Amendment 84 #
Proposal for a directive – amending act Article 1 – point 8 Directive 2001/83/EC Article 54 – point o) ‘(o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals
Amendment 85 #
Proposal for a directive – amending act Article 1 – point 8 Directive 2001/83/EC Article 54 – point o – subparagraph 1 a (new) These safety features shall be applied without discrimination among marketing channels.
Amendment 86 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 2 – point b – subparagraph 1 a (new) Amendment 87 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 2 – point b – subparagraph 1 a (new) Safety features shall be considered equivalent when they offer the same level of efficacy for ascertaining identification, authentication, traceability and absence of tampering, as well as the same level of technical difficulty for duplication. When removing, replacing or covering the safety feature, this point should also be applicable to the new safety feature, unless the primary safety feature is a covert one and can therefore not be recognised.
Amendment 88 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 2 – point c a (new) (ca) The manufacturing authorisation holder clearly indicates on the outer packaging when original safety features have been partly or fully removed or covered up;
Amendment 89 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 2 – subparagraph 1 a (new) The safety features referred to in point (o) of Article 54 shall be applied without discriminating between distribution channels.
Amendment 90 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 3 (3) Manufacturing authorisation holders
Amendment 91 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 1 (4) The Commission shall adopt the measures necessary for the implementation of point (o) of Article 54 and of paragraphs (1) and (2) of this Article. Before a specific measure is proposed in accordance with point (o) of Article 54, the Commission shall carry out a public impact assessment on the costs and benefits of existing safety features, as well as a consultation with the parties involved in the implementation and use of such safety features.
Amendment 92 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 4. The Commission shall adopt the measures necessary for the implementation of point (o) of Article 54 and of paragraphs (1) and (2) of this Article. Before formulating a specific proposal as provided for by Article 54(o), the Commission shall perform an impact assessment of the costs and benefits of the anti-counterfeiting systems currently in force and consult interested parties about the implementation and use of such authenticating seals. Those measures, designed to amend non-essential elements of this Directive by supplementing it, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 121(2a)
Amendment 93 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 2 a (new) Before the Commission adopts a measure to implement Article 54(o), it shall perform a public impact assessment of the costs and benefits of the existing safety features and consult all parties involved in implementing and using such safety features.
Amendment 94 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 3 – point e a (new) (ea) if the product is delivered directly, without the involvement of third parties, such as wholesale distributors, traders or brokers, to a healthcare setting in which the product is administered directly to the patient.
Amendment 95 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights.
Amendment 96 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 a (new) Member States shall ensure that both the ownership and the confidentiality of the data elicited in applying the safety features for the purpose of identifying medicinal products are respected.
Amendment 97 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate
Amendment 98 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 a (new) (4a) Paragraphs 2 and 3 shall also apply to a manufacturing authorisation holder who partly or fully removes or covers-up safety features that are applied on a voluntary basis to medicinal products that are subject to medical prescription by the original manufacturer for purposes referred to in paragraph 2 of this Article.
Amendment 99 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54 a – paragraph 4 a (new) As from [insert concrete date 36 months after publication] all medicinal products subject to medical prescription other than radiopharmaceuticals must, from the time of the batch release pursuant to Article 51, carry a serialisation number that identifies the individual package unequivocally. The serial number should be integrated into an internationally recognised and harmonised coding standard.
source: PE-439.067
2010/02/22
IMCO
46 amendments...
Amendment 11 #
Proposal for a directive – amending act Recital 3 (3) Past experience shows that such medicinal products are not only marketed through illegal supply chains, but reach the patient via the legal supply chain as well. This poses a particular threat to human health and may lead to a lack of trust of the patient in the legal supply chain. All this is due to poor enforcement of intellectual property rights in the EU. Improved enforcement of intellectual property rights is needed in all sectors of the internal market in order to prevent counterfeiting in general and the manufacture of counterfeit medicinal products in particular. The rules contained in Directive 2001/83/EC should be amended in order to respond to this increasing threat.
Amendment 12 #
Proposal for a directive – amending act Recital 3 a (new) (3a) The Commission should, in cooperation with the European Medicines Agency and the authorities of the Member State, launch a campaign informing consumers of the authentication measures already in place, of the overt safety features (such as safety seals) on the packaging of medicinal products, and of the risks involved in purchasing falsified medicinal products. In particular, the campaign should raise consumer awareness of the risks involved in purchasing medicinal products from unauthorised and unlicensed online sources.
Amendment 13 #
Proposal for a directive – amending act Recital 3 a (new) (3a) Experience shows that, when consumers purchase medicinal products on the internet, they cannot always verify the authenticity of the source. The Commission, in coordination with the EMA and the Member States, should launch campaigns to raise awareness among consumers of the risks they run in obtaining medicines over the internet from unlicensed sites. Further, the Commission should report every two years to the European Parliament and to the Council on the impact of the measures provided for by this Directive and the need for further harmonisation, with particular regard to the sale of medicines on the internet, whereby the decision on whether or not to authorise the sale of medicines on the internet rests with each Member State.
Amendment 14 #
Proposal for a directive – amending act Recital 3 b (new) Amendment 15 #
Proposal for a directive – amending act Recital 3 c (new) (3c) Every two years the Commission should submit a comprehensive evaluation of the situation regarding 'over-the-counter' medicinal products (OTCs), focusing on the question of whether and in what form OTCs should be included in the scope of this Directive.
Amendment 16 #
Proposal for a directive – amending act Recital 4 a (new) (4a) Citizens of the Union should be made aware of the danger to their health of ordering products from non-controlled internet websites or from the illegal supply chain. The Commission, together with the Member States and in cooperation with patients' and consumers´ organisations, should adopt measures to increase awareness among the general public of the risks involved in purchasing medicinal products via the internet.
Amendment 17 #
Proposal for a directive – amending act Recital 5 (5) Today’s distribution network for medicinal products is increasingly complex and involves many players which are not necessarily wholesale distributors as defined in Directive 2001/83/EC. In order
Amendment 18 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing obligatory safety features for prescription medicinal products, due account should be taken of the particularities of certain products or categories of products, such as generic medicines. This includes the risk of
Amendment 19 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and
Amendment 20 #
Proposal for a directive – amending act Recital 7 a (new) Amendment 21 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, working together with stakeholders, should be free to determine the particular aspects of medicines authentication which they believe are most appropriate for their medicine distribution system, taking into account the safety features adopted pursuant to this Directive.
Amendment 22 #
Proposal for a directive – amending act Recital 7 b (new) (7b) In order to provide patients with timely protection from the risks of falsified medicinal products, a manufacturing authorisation holder who partly or fully removes or covers up safety features that are applied on a voluntary basis should be required to replace such safety features with equivalent safety features designed to ensure the identification, authentication and traceability of prescription medicinal products as soon as this Directive enters into force.
Amendment 23 #
Proposal for a directive – amending act Recital 8 (8) Any actor in the supply chain who
Amendment 24 #
Proposal for a directive – amending act Recital 8 a (new) (8a) In order to provide patients with timely protection from the risks of falsified medicinal products, a manufacturing authorisation holder who partly or fully removes or covers-up safety features that are applied on a voluntary basis should be required to replace such safety features with equivalent safety features designed to ensure the identification, authentication and traceability of prescription medicinal products as soon as this Directive enters into force.
Amendment 25 #
Proposal for a directive – amending act Recital 17 (17) In particular the Commission should be empowered to adopt measures regarding safety features that shall appear on the packaging of medicinal products
Amendment 26 #
Proposal for a directive – amending act Recital 18 a (new) (18a) Member States should cooperate with Europol, inter alia, in order to strengthen the application of existing restrictions regarding the illegal supply of medicinal products on the internet.
Amendment 27 #
Proposal for a directive – amending act Recital 18 a (new) (18a) Member States should reinforce their cooperation in the fields of justice and police, including through Europol, to enforce existing restrictions on the illegal supply of medicinal products via the internet.
Amendment 28 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83(EC) Article 1 – point 2 a (new) -1) In Article 1, the following point 2a is inserted after point 2: "2a. Falsified medicinal product: Any medicinal product, ingredient, excipient or component thereof which is deliberately and / or fraudulently misrepresented with respect to: (a) its identity, including its packaging and labelling, name, composition in respect of any of its components and strength; and/or (b) its source, including the manufacturer, country of manufacture, country of origin, marketing authorisation holder; and/or (c) its history, including the records and documents relating to distribution channels. This definition is without prejudice to legislation on intellectual and industrial property rights."
Amendment 29 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83(EC) Article 1 – point 2 a (new) -1) In Article 1, the following point 2a is inserted after point 2: "2a." Falsified medicinal product Any product with a false representation (1) of its identity (2) and/or source (3). This definition covers the product itself, its container or other packaging or labelling information. A falsified medicinal product may be either branded or generic.. A falsified medicinal products may include products with the correct ingredients/components(4), with the wrong ingredients/components, without active ingredients, with incorrect amounts of active ingredients, or with false packaging. Infringements or disputes concerning patents must be distinguished from counterfeiting or falsification of medicinal products. Medicinal products (whether generic or branded) that are not authorized for marketing in a given country but authorized elsewhere shall not be considered falsified. Sub-standard batches or quality defects or non-compliance with Good Manufacturing Practices/Good Distribution Practices (GMP/GDP) in legitimate medicinal products shall not be considered falsified. Notes: (1) Falsification of medicinal products is fraudulent and deliberate. Criminal intent and/or negligence shall be factors to be taken into account during the legal procedure for the purposes of imposing sanctions. (2) This includes any misleading statement with respect to the name, composition, strength, or other elements. (3) It also includes any misleading statement with respect to the manufacturer, country of manufacture, country of origin, marketing authorization holder or distribution chain. (4) It refers to all the components of a medicinal product."
Amendment 30 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83(EC) Article 1 – point 5 a (new) -1) In Article 1, the following point 5a is inserted after point 5: "5a. Falsified medicinal product: Any medicinal product that has been intentionally or deliberately falsified in relation to its: (a) identity, including its packaging, labelling, name and composition in terms of both ingredients, including excipients and active ingredients, and the dosage thereof; and/or (b) source, including the manufacturer, the country of manufacture, the country of origin and the marketing authorisation holder; and/or (c) history, including the registers and documents enabling the distribution chain to be identified. The Commission shall be empowered to update this definition on the basis of technical and scientific progress and/or international agreements."
Amendment 31 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83(EC) Article 1 – point 5 a (new) -1) In Article 1, the following point 5a is inserted after point 5: "5a. Falsified medicinal product: Any medicinal product that has been deliberately falsified in relation to its: (a) identity, including its packaging, labelling, name or composition in terms of both ingredients, including excipients and active ingredients, or the dosage thereof; (b) source, including the manufacturer, the country of manufacture, the country of origin or the marketing authorisation holder; (c) history, including the registers or documents enabling the distribution chain to be identified. The Commission shall, in cooperation with the Agency and the authorities of the Member States , update this definition on the basis of technical and scientific progress and international agreements. This definition is without prejudice to legislation on intellectual and industrial property rights. This definition does not cover manufacturing errors."
Amendment 32 #
Proposal for a directive – amending act Article 1 – point 2 a (new) Directive 2001/83(EC) Article 2 – paragraph 3 a (new) (2a) In Article 2, the following paragraph 3a is inserted after paragraph 3: "3a. Nothing in this Directive shall affect the right of Member States to restrict or prohibit the sale of prescription medicines via the internet."
Amendment 33 #
Proposal for a directive – amending act Article 1 – point 8 Directive 2001/83(EC) Article 54 – point o '(o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, subject to medicinal prescription as defined in Title VI. Safety features are mandatory for all medicines listed in a restricted list of medicinal products conceived and developed together by the Commission and the Member States in consultation with stakeholders, including patients' organisations.'
Amendment 34 #
Proposal for a directive – amending act Article 1 – point 8 Directive 2001/83(EC) Article 54 – point o safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals
Amendment 35 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 1 – point c a (new) (ca) keep the additional costs as low as possible and spread additional costs along the supply chain.
Amendment 36 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 2 – point b a (new) (ba) Manufacturing authorisation holders clearly indicate on the outer packaging when original safety features have been partly or fully removed or covered up;
Amendment 37 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 2 – introductory part (2) The safety features referred to in point (o) of Article 54 shall not be partly or fully removed or covered-up, unless the identification, authenticity and traceability of the medicinal products are guaranteed and the following conditions are fulfilled:
Amendment 38 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 2 - subparagraph 1 (2) The safety features referred to in point (o) of Article 54 shall not be partly or fully removed or covered
Amendment 39 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 2 - point b – subparagraph 1 a (new) Safety features shall be considered equivalent when they offer the same level of efficacy for ascertaining identification, authentication, traceability and absence of tampering, as well as the same level of technical difficulty of duplication. When removing, replacing or covering up the safety feature, this condition shall also apply to the new safety feature, unless the primary safety feature is a covert one and can therefore not be recognised.
Amendment 40 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 1 (4) The Commission shall adopt the measures necessary for the implementation of point (o) of Article 54 and of paragraphs (1) and (2) of this Article. However, before proposing specific measures in accordance with point (o) of Article 54, the Commission shall undertake a public cost-benefit evaluation of existing safety features and consult the stakeholder parties involved in applying and using the safety features.
Amendment 41 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 1 (4) The Commission shall adopt the measures necessary for the implementation of point (o) of Article 54 and of paragraphs (1) and (2) of this Article. Before a specific measure is proposed in accordance with point (o) of Article 54, the Commission shall carry out a public impact assessment of the costs and benefits of existing safety features, as well as a consultation with the parties involved in the implementation and use of such safety features.
Amendment 42 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 3 – point a a (new) (aa) the complexity of the supply chain;
Amendment 43 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 3 – point b (b) the number of incidences of falsifications
Amendment 44 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 3 – point e – subparagraph 1a (new) The safety features (other than serialisation numbering) shall be imposed through the identification of one or more categories of feature that must be used for particular products or categories of product. The Commission’s Pharmaceutical Committee shall define categories comprising safety features offering equivalent efficiency and effectiveness, and features from the same category shall then be considered equivalent for the purposes of paragraph (2) (b) of this Article. Manufacturing authorization holders shall have discretion as to which specific feature or features to use within a category, unless the Commission specifies reasons for requiring that a particular safety feature be used.
Amendment 45 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights. Member States shall ensure that the ownership and confidentiality of the data resulting from the use of safety features with the object of demonstrating the authenticity of pharmaceutical products are respected.’
Amendment 46 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights. Member States shall ensure that the ownership and confidentiality of data generated by the use of safety features to authenticate medicinal products shall be respected.
Amendment 47 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – paragraph 4 – subparagraph 5 a (new) The measures referred to in this paragraph shall take due account of at least all of the following: (a) The cost effectiveness of the system, in order to ensure that any measure that is applied is based on a cost benefit analysis. (b) The costs relating to the measures shall be shared proportionately by all the actors in the supply chain and be linked to the price of the medicinal product concerned. (c) The independence of the system and the legitimate interest in protecting information of a commercially confidential nature and the protection of industrial and commercial property rights and of personal data.
Amendment 48 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83(EC) Article 54a – Paragraph 4 a (new) (4a) Paragraphs 2 and 3 shall also apply to a manufacturing authorisation holder who partly or fully removes or covers-up safety features that are applied on a voluntary basis to medicinal products that are subject to medical prescription by the original manufacturer for the purposes referred to in paragraph (2) of this Article.
Amendment 49 #
Proposal for a directive – amending act Article 1 – point 14 Directive 2001/83(EC) Article 85 c (new) Article 85c The Commission, together with the Member States, shall certify, and establish a register of accredited internet pharmacies. Such a register shall be accessible via a public database. The Commission shall establish a Community quality certification logo to be affixed on the webpages of the legitimate internet pharmacies. The Commission shall ensure that none of the non-accredited pharmacies use the Community logo, or trade in medicinal products in the internal market.
Amendment 50 #
Proposal for a directive – amending act Article 1 – point 14 Directive 2001/83(EC) Article 85 d (new) Article 85d 1. The Commission and Member States shall adopt measures to increase awareness among the general public of the risks related to purchasing medicinal products on the internet, which may include: - warnings appearing at the top of the internet page in search engines in the event of a search for medicinal products on the internet; - information campaigns, in cooperation with the Member States and patients' and consumers' organisations; - providing an easily accessible list of accredited internet pharmacies; Those measures, designed to amend non- essential elements of this Directive by supplementing it, shall be adopted in accordance with the procedure referred to in Article 290 of the Treaty on the Functioning of the European Union.
Amendment 51 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83(EC) Article 118 b The Member States shall lay down the rules on penalties applicable to infringements of the national provisions adopted pursuant to this Directive and shall take all measures necessary to ensure that they are implemented. Applicable penalties shall take into account the threat to public health represented by the falsification of medicinal products. The penalties provided for must be harmonised, effective, proportionate and dissuasive. The Member States shall notify those provisions to the Commission by [insert concrete date 18 months after publication] at the latest and shall notify it without delay of any subsequent amendment affecting them.
Amendment 52 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83(EC) Article 118 b a (new) Article 118 ba The Commission shall establish a network between the Commission, the Agency and the competent authorities of the Member States and involve patients' and consumers' organisations in order to ensure the exchange of information on the measures taken to combat the falsification of medicinal products, including on the penalties systems in place.
Amendment 53 #
Proposal for a directive – amending act Article 2 – paragraph 1 – subparagraph 3 – point -a (new) (-a) the provisions necessary to comply with Article 1(9) in so far as it relates to Article 54a(5) and Articles 54a(2) and 54a(3) to the extent they are referred to 54a(5) of Directive 2001/83/EC as amended by this Directive from [insert actual date 6 months after publication];
Amendment 54 #
Proposal for a directive – amending act Article 2 – paragraph 1 – subparagraph 3 – point b (b) the provisions necessary to comply with Article 1(6),
Amendment 55 #
Proposal for a directive – amending act Article 2 – paragraph 1 – subparagraph 3 – point b a (new) (ba) the provisions necessary to comply with Article 1(9) except in so far as it relates to Article 54a(5) and Articles 54a(2) and 54a(3) to the extent they are referred to 54a(5) of Directive 2001/83/EC as amended by this Directive from [insert actual date 48 months after publication].
Amendment 56 #
Proposal for a directive – amending act Article 2 – paragraph 2 Member States shall communicate to the Commission the text of the main provisions of national law which they adopt in the field covered by this Directive. This Directive shall not affect the right of Member States to restrict or ban the sale of prescription drugs via the internet.
source: PE-439.069
2010/03/12
ENVI
324 amendments...
Amendment 100 #
Proposal for a directive – amending act Recital 12 (12) Falsified active pharmaceutical ingredients pose the risk of sub-standard active pharmaceutical ingredients. This risk should be addressed
Amendment 101 #
Proposal for a directive – amending act Recital 13 (13)
Amendment 102 #
Proposal for a directive – amending act Recital 13 (13) The manufacture of active pharmaceutical ingredients should be subject to good manufacturing practices irrespective of whether those ingredients were manufactured in the Community of imported. With regard to the manufacture of active pharmaceutical ingredients or excipients in third countries, it should be ensured that the rules for the manufacture of active
Amendment 103 #
Proposal for a directive – amending act Recital 13 (13) The manufacture of active pharmaceutical ingredients should be subject to good manufacturing practices irrespective of whether those ingredients were manufactured in the Community or imported. With regard to the manufacture of active pharmaceutical ingredients in third countries, it should be ensured that the rules for the manufacture of active pharmaceutical ingredients intended for export to the Community, including inspection and enforcement, provide for a level of protection of public health equivalent to that provided for by Community legislation.
Amendment 104 #
Proposal for a directive – amending act Recital 13 a (new) Amendment 105 #
Proposal for a directive – amending act Recital 13 a (new) (13a) Where good manufacturing practices for excipients or equivalent systems are already in place and well- regulated, they should be taken into account in this Directive.
Amendment 106 #
Proposal for a directive – amending act Recital 14 (14) In order to facilitate enforcement and control of Community rules relating to active substances used as starting material, the manufacturers
Amendment 107 #
Proposal for a directive – amending act Recital 14 a (new) (14a) Counterfeit medicinal products are often found to have been supplied in response to orders placed over the Internet. In accordance with the provisions of the Treaty, particularly Article 168 of the TFEU, Member States are responsible for regulating the marketing of medicinal products at the last level of trade, particularly in pharmacies. This also includes regulating the marketing of medicinal products by mail order and over the Internet. The case law of the Court of Justice permits Member States to impose an absolute ban on the supply of prescription medicines by mail order, in accordance with the wide margin of discretion which they enjoy on account of the dangers associated with this method of marketing.
Amendment 108 #
Proposal for a directive – amending act Recital 15 (15) To ensure a similar level of protection of human health throughout the Community, and to avoid distortions in the internal market, the harmonised principles and guidelines for inspections of holders of manufacturing and wholesaler authorisations of medicinal products as well as manufacturers and distributors of active substances should be strengthened. This should also help to ensure the functioning of existing mutual recognition agreements which rely on efficient and comparable inspection and enforcement throughout the Community.
Amendment 109 #
Proposal for a directive – amending act Recital 15 a (new) (15a) Member States should impose effective sanctions for acts related to falsified medicines. Those sanctions should at least be equivalent to those typically applied for illegal acts related to narcotics. The Commission may issue general guidelines for such an effective criminal sanctions regime. Specific provisions should be included in Directive 2001/83/EC for enforcing the new safety feature requirements. In cases of authorised or otherwise legitimate medicinal products with quality defects due to mistakes in the manufacturing or subsequent handling, the relevant Union or national legislation shall apply.
Amendment 110 #
Proposal for a directive – amending act Recital 15 a (new) (15a) It is necessary for the operation of the internal market to establish EU-wide harmonised safety features for medicinal products. The technical implementation of these features and the design of the test methods should, however, be left to the Member States in accordance with the principle of subsidiarity.
Amendment 111 #
Proposal for a directive – amending act Recital 16 (16)
Amendment 112 #
Proposal for a directive – amending act Recital 17 (17) In particular the Commission should be empowered to adopt
Amendment 113 #
Proposal for a directive – amending act Recital 17 (17) In particular the Commission should be empowered to adopt
Amendment 114 #
Proposal for a directive – amending act Recital 17 a (new) (17a) 36 months at the latest after entry into force of this Directive, the traceability procedure for medicinal products should be harmonised at EU level. Hence, each medicinal product should be unequivocally identified by means of a serial number on its individual packaging.
Amendment 115 #
Proposal for a directive – amending act Recital 18 a (new) (18a) The Member States should cooperate to enforce existing restrictions on illegal trading in medicinal products, including by means of Europol.
Amendment 116 #
Proposal for a directive – amending act Recital 18 a (new) (18a) Member States should collaborate, including through Europol, to enforce existing restrictions on the illegal internet supply of medicines.
Amendment 117 #
Proposal for a directive – amending act Recital 18 a (new) (18a) Furthermore, Member States should collaborate, making use of the services of Europol, to enforce the existing restrictions on the illegal internet supply of medicines.
Amendment 118 #
Proposal for a directive – amending act Recital 18 a (new) (18a) The Member States should collaborate, within Europol and elsewhere, in enforcing existing rules designed to restrict the illegal activities of those supplying medicinal products over the internet.
Amendment 119 #
Proposal for a directive – amending act Recital 18 a (new) Member States should cooperate with each other, and with Europol, to step up the existing restrictions on the illegal supply of pharmaceuticals over the internet.
Amendment 120 #
Proposal for a directive – amending act Recital 18 a (new) (18a) Counterfeit medicinal products are often found to have been supplied in response to orders placed over the Internet. In accordance with the provisions of the Treaty, particularly Article 168 of the TFEU, Member States are responsible for regulating the marketing of medicinal products at the last level of trade, particularly in pharmacies. This also includes regulating the marketing of medicinal products by mail order and over the Internet. The case law of the Court of Justice permits Member States to impose an absolute ban on the supply of prescription medicines by mail order, in accordance with the wide margin of discretion which they enjoy on account of the dangers associated with this method of marketing.
Amendment 121 #
Proposal for a directive – amending act Recital 18 a (new) Amendment 122 #
Proposal for a directive – amending act Recital 18 a (new) (18b) It is necessary for the operation of the internal market to establish EU-wide harmonised safety features for medicinal products. The technical implementation of these features and the design of the test methods should, however, be left to the Member States in accordance with the principle of subsidiarity.
Amendment 123 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - introductory part (new) -1) In Article 1, the following point 2a is inserted after point 2: 2a. Falsified medicinal product: Any medicinal product, ingredient, excipient or component thereof which is deliberately and / or fraudulently misrepresented with respect to:
Amendment 124 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - introductory part (new) -1) In Article 1, the following point 2a is inserted after point 2: 2a. Falsified medicinal product: Any medicinal product with a false representation, made fraudulently and deliberately, of:
Amendment 125 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - introductory part (new) -1) In Article 1, the following point 2a is inserted after point 2: 2a. Falsified medicinal product: Any medicinal product that has been deliberately falsified in relation to its:
Amendment 126 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - introductory part (new) -1) In Article 1, the following point 2a is inserted after point 2: 2a. Falsified medicinal product: Any medicinal product that has been deliberately falsified in relation to its:
Amendment 127 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - introductory part (new) -1) In Article 1, the following point 2a is inserted after point 2: 2a. Falsified medicinal product: Any medicinal product which has been deliberately falsified with regard to its:
Amendment 128 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - introductory part (new) -1) In Article 1, the following point 2a is inserted after point 2: 2a. Falsified medicinal product: Any medicinal product with a false or misleading representation of:
Amendment 129 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - introductory part (new) Amendment 130 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point a (new) (a) its identity, including any misleading statement with respect to its packaging and labelling, name, composition in respect of any of its components and strength, or other elements; and/or
Amendment 131 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point a (new) (a) identity, including its packaging, labelling, name and composition in terms of components, including packaging components, excipients, active ingredients, and the dosage thereof; and/or
Amendment 132 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point a (new) (a) identity, including its packaging, labelling, name and composition in terms of both ingredients, including excipients and active ingredients, and the dosage thereof;
Amendment 133 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point a (new) (a) its identity, including its packaging and labelling, name, composition in respect of any of its components and strength; and/or
Amendment 134 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point a (new) (a) its identity, including its packaging and labelling, name, composition in respect of any of its components and strength; and/or
Amendment 135 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point a (new) (a) properties, including packaging, labelling, designation and formulation, as regards both the active pharmaceutical ingredients and their dosage;
Amendment 136 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point a (new) a) its identity, including its packaging and labelling and package leaflet, name, composition in respect of any of its components and strength; and/or
Amendment 137 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point b (new) (b) its source, including any misleading statement with respect to the manufacturer, country of manufacturing, country of origin, marketing authorisation holder, steps of distribution; and/or
Amendment 138 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point b (new) (b) production, including the manufacturer, the country of manufacture, the country of origin and the marketing authorisation holder;
Amendment 139 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point b (new) b) its source, including the manufacturer, country of manufacture, country of origin and marketing authorisation holder; and/or
Amendment 140 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point b (new) (b) its source, including the manufacturer, country of manufacturing, country of origin, marketing authorisation holder; and/or
Amendment 141 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point b (new) (b) its source, including the manufacturer, country of manufacturing, country of origin, marketing authorisation holder; and/or
Amendment 142 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point b (new) (b) source, including the manufacturer, the country of manufacture, the country of origin and the marketing authorisation holder; and/or
Amendment 143 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point b (new) (b) source, including the manufacturer, the country of origin and the marketing authorisation holder;
Amendment 144 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point c (new) (c) its history, including the records and documents relating to distribution channels. This applies to the product, its container or other packaging or labelling information.
Amendment 145 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point c (new) (c) history, including the registers and documents enabling the distribution chain to be identified.
Amendment 146 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point c (new) (c) history, including the records and documents enabling the distribution chain to be identified.
Amendment 147 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point c (new) (c) its origin, including the records and documents relating to identification of the distribution chain.
Amendment 148 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point c (new) c) its history, including the records and documents relating to distribution channels.
Amendment 149 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point c (new) Amendment 150 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 1 - point c (new) (c) its history, including the records and documents relating to distribution channels.
Amendment 151 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 2 (new) The Commission shall, in cooperation with the Agency and Member State authorities, update this definition on the basis of technical and scientific progress and international agreements. This definition is not related to infringements of legislation on intellectual and industrial property rights or patent rights. This definition does not include non- intentional manufacturing errors.
Amendment 152 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 2 (new) The Commission shall be empowered to update this definition on the basis of technical and scientific progress and international agreements. This definition is not related to infringements of legislation on intellectual and industrial property rights or patent rights. This definition does not include manufacturing errors.
Amendment 153 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 2 (new) The Commission shall adapt this definition in accordance both with technical and scientific progress and with international agreements. This definition shall not concern infringements of legislation on industrial property rights. This definition shall not include production faults.
Amendment 154 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 2 (new) This definition is not related to infringements of legislation on intellectual and industrial property rights or patent rights.
Amendment 155 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 2 (new) This definition is not related to infringements of legislation on intellectual and industrial property rights or patent rights.
Amendment 156 #
Proposal for a directive – amending act Article 1 – point -1 (new) Directive 2001/83/EC Article 1 – point 2 a - paragraph 2 (new) This definition is not related to infringements of legislation on intellectual and industrial property rights or patent rights.
Amendment 157 #
Proposal for a directive – amending act Article 1 – point -1 a (new) Directive 2001/83/EC Article 1 – point 2 b (new) (-1a) In Article 1, the following point 2b is inserted after point 2a: 2b. Active substance used as starting material: Any substance or mixture of substances intended to be used in the manufacture of a medicinal product and that, when used in its production, becomes an active ingredient of that product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.
Amendment 158 #
Proposal for a directive – amending act Article 1 – point - 1 b (new) Directive 2001/83/EC Article 1 – point 3 a (new) (-1b) In Article 1, the following point 3a is inserted after point 3: 3a. Excipient: The constituent of a pharmaceutical form apart from the active substance. Excipients include fillers, disintegrants, lubricants, colouring matters, antioxidants, preservatives, adjuvants, stabilisers, thickeners, emulsifiers, solubilisers, permeation enhancers, flavouring and aromatic substances, as well as the constituents of the outer covering of the medicinal products, for instance gelatine capsules.
Amendment 159 #
Proposal for a directive – amending act Article 1 – point 1 Directive 2001/83/EC Article 1 – point 17 a 17a. T
Amendment 160 #
Proposal for a directive – amending act Article 1 – point 1 Directive 2001/83/EC Article 1 – point 17 a ‘17a. Trading
Amendment 161 #
Proposal for a directive – amending act Article 1 – point 1 Directive 2001/83/EC Article 1 – point 17 a ‘17a. Trading
Amendment 162 #
Proposal for a directive – amending act Article 1 – point 1 a (new) Directive 2001/83/EC Article 1 – point 17 b (new) (1a) In Article 1, the following point 17b is inserted after point 17a: 17b. Persons authorised to supply medicinal products: Persons or entities in possession of a wholesale distribution authorisation without prejudice to persons or entities exempt from holding an authorisation to supply medicinal products.
Amendment 163 #
Proposal for a directive – amending act Article 1 – point 1 a (new) Directive 2001/83/EC Article 1 – point 17 b (new) (1a) In Article 1, the following point 17b is inserted after point 17a: 17b. Persons authorised to supply medicinal products: Persons or entities in possession of a wholesale distribution authorisation without prejudice to persons or entities exempt from holding an authorisation to supply medicinal products.
Amendment 164 #
Proposal for a directive – amending act Article 1 – point 1 a (new) Directive 2001/83/EC Article 1 – point 17 b (new) (1a) In Article 1, the following point 17b is inserted after point 17a: 17b. Brokering: All activities in relation to sale or purchase of medicinal products or active pharmaceutical ingredients except for retail supply and wholesale distribution as defined in point 17 of this Article, that do not include physical handling and that consist of mediating independently and on behalf of another legal or natural person.
Amendment 165 #
Proposal for a directive – amending act Article 1 – point 1 a (new) Directive 2001/83/EC Article 1 – point 17 b (new) (1a) In Article 1, the following point 17b is inserted after point 17a: 17b. Brokering: All activities in relation to sale or purchase of medicinal products or active pharmaceutical ingredients, except for retail supply and wholesale distribution as defined in point 17 of this Article, that do not include physical handling and that consist of mediating independently and on behalf of another legal or natural person.
Amendment 166 #
Proposal for a directive – amending act Article 1 – point 1 a (new) Directive 2001/83/EC Article 1 – point 17 b (new) Amendment 167 #
Proposal for a directive – amending act Article 1 – point 2 a (new) Directive 2001/83/EC Article 2 – paragraph 3 a (new) (2a) In Article 2, the following paragraph 3a is inserted after paragraph 3: 3a. The provisions of this Directive shall be without prejudice to the right of the Member States to restrict or prohibit trading in prescription medicinal products over the Internet.
Amendment 168 #
Proposal for a directive – amending act Article 1 – point 2 a (new) Directive 2001/83/EC Article 2 – paragraph 3 a (new) (2a) In Article 2, the following paragraph 3a is inserted after paragraph 3: 3a. Nothing in this Directive shall affect the right of Member States to restrict or prohibit the sale of prescription medicines over the internet.
Amendment 169 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 Amendment 170 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f - subparagraph 1 (f) to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances and excipients, which have been manufactured and distributed in accordance with the detailed guidelines on good manufacturing and distribution practices for starting materials. To this end, the holder of the manufacturing authorization shall verify compliance of the active substances
Amendment 171 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 (f) to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured and distributed in accordance with the detailed guidelines on good manufacturing and distribution practices for starting materials. To this end, the holder of the manufacturing authorization shall verify compliance of the active substances manufacturer with good manufacturing practices by himself or through a body accredited for this purpose by the competent authority of a Member State.
Amendment 172 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 f) to comply with the principles and guidelines of good manufacturing practice
Amendment 173 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 (f) to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting materials. To this end, the holder of the manufacturing authorization shall verify compliance of the active substances manufacturer with good manufacturing practices by himself, another holder of a manufacturing authorisation obtaining the same material from this manufacturer or through a body accredited for this purpose by the competent authority of a Member State.
Amendment 174 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 (f) to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting materials. To this end, the holder of the manufacturing authorization shall verify compliance of the active substances manufacturer with good manufacturing practices by himself or through a body accredited for this purpose by the competent authority of a Member State. The manufacturing authorisation holder should ensure that starting materials other than active pharmaceutical ingredients are assessed as being suitable for use in pharmaceutical products. The manufacturing authorisation holder must ensure that the process by which the assessment is achieved is described in a quality system which will be available for inspection by competent authorities.’
Amendment 175 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 (f) to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting materials. To this end, the holder of the manufacturing authorization shall verify compliance of the active substances manufacturer with good manufacturing practices by himself or through a body accredited for this purpose by the competent authority of a Member State. Excipients which comply with equivalent good manufacturing practice and good distribution practice, such as IPEC-PQG, EFfCI, HACCP and/or ISO9001/ISO22000, are exempted from further requirements.
Amendment 176 #
Proposal for a directive – amending act Article 1 – point 3 – point a Directive 2001/83/EC Article 46 – point f – subparagraph 1 f) to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting materials. To this end, the holder of the manufacturing authorization shall verify compliance of the active substances manufacturer with good manufacturing practices
Amendment 177 #
Proposal for a directive – amending act Article 1 – point 3 – point a a (new) Directive 2001/83/EC Article 46 – point f – subparagraph 2 (aa) The second subparagraph of point (f) is replaced by the following: The Commission shall adopt, by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c, a list of certain categories of excipients identified on a risk-based approach taking into account their source and their intended use. For these categories of excipients, the manufacturer shall apply the appropriate good manufacturing practices on the basis of a formalised risk assessment in accordance with the applicable guidelines referred to in the second paragraph of Article 47, taking into account other suitable quality system requirements, and document this.
Amendment 178 #
Proposal for a directive – amending act Article 1 – point 3 – point a a (new) Directive 2001/83/EC Article 46 – point f – subparagraph 2 (aa) The second subparagraph of point (f) is replaced by the following: The Commission shall establish, by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c, a list of certain categories of excipients identified on a risk-based approach taking into account their source and their intended use. For these categories of excipients, the manufacturer shall apply the appropriate good manufacturing practices on the basis of a formalised risk assessment in accordance with the applicable guidelines referred to in the second paragraph of Article 47, taking into account other suitable quality system requirements, and document this.
Amendment 179 #
Proposal for a directive – amending act Article 1 – point 3 – point a a (new) Directive 2001/83/EC Article 46 – point f – subparagraph 2 (aa) The second subparagraph of point (f) is replaced by the following: This point shall also be applicable to certain excipients, the list of which as well as the specific conditions of application of which shall be established by the Commission by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c. Only excipients which have been manufactured in accordance with the standards for quality control of ISO 9000/ISO 9001 should be used in medicinal products.
Amendment 180 #
Proposal for a directive – amending act Article 1 – point 3 - point a a (new) Directive 2001/83/EC Article 46 - point f - subparagraph 2 Amendment 181 #
Proposal for a directive – amending act Article 1 – point 3 – point b Directive 2001/83/EC Article 46 – point g (b) The following point (g) is added: ‘(g) to inform the competent authority of products he gets knowledge of which are or which are suspected to be falsified in relation to the identity, history or source of products manufactured by him either in the legal supply chain or being sold by means of illegal internet trade.
Amendment 182 #
Proposal for a directive – amending act Article 1 – point 3 – point b Directive 2001/83/EC Article 46 – point g (b) The following point (g) is added: ‘(g) to inform the competent authority of products he gets knowledge of which are or which are suspected to be falsified in relation to the identity, history or source of products manufactured by him either in the legal supply chain or being sold by means of illegal internet trade.
Amendment 183 #
Proposal for a directive – amending act Article 1 – point 3 – point b Directive 2001/83/EC Article 46 – point g (b) The following point (g) is added:
Amendment 184 #
Proposal for a directive – amending act Article 1 – point 3 – point b a (new) Directive 2001/83/EC Article 46 – point h Amendment 185 #
Proposal for a directive – amending act Article 1 – point 3 – point b a (new) Directive 2001/83/EC Article 46 – point h (ba) The following point (h) is added: h) In the light of this Directive the Commission shall submit to the European Parliament and to the Council a statistical report with reliable and accurate data on the current situation, trends and developments in counterfeiting/falsified medicines in the Member States on a yearly basis. That report shall clearly distinguish counterfeiting/falsified medicines from patent infringement.
Amendment 186 #
Proposal for a directive – amending act Article 1 – point 3 – point b a (new) Directive 2001/83/EC Article 46 – point h (ba) The following point (h) is added: (h) In the light of this Directive the Commission shall submit to the European Parliament and to the Council a statistical report with reliable and accurate data on the current situation, trends and developments concerning falsified medicines in the Member States on a yearly basis. This report shall clearly distinguish falsified medicines from patent infringement.
Amendment 187 #
Proposal for a directive – amending act Article 1 – point 3 – point b a (new) Directive 2001/83/EC Article 46 – point h (ba) The following point (h) is added: (h) to assume legal liability for the accuracy of the findings of inspections and checks he has carried out or commissioned, without it being possible to delegate that liability.
Amendment 188 #
Proposal for a directive – amending act Article 1 – point 4 Directive 2001/83/EC Article 46b – paragraph 1 (1) Member States shall take appropriate measures to ensure that the manufacture and distribution on their territory of active substances used as starting material, including active substances that are intended for export, complies with good manufacturing
Amendment 189 #
Proposal for a directive – amending act Article 1 – point 4 Directive 2001/83/EC Article 46b – paragraph 2 – introductory part 2. Active substances used as starting material
Amendment 190 #
Proposal for a directive – amending act Article 1 – point 4 Directive 2001/83/EC Article 46b – paragraph 2 – point b (b) they
Amendment 191 #
Proposal for a directive – amending act Article 1 – point 4 Directive 2001/83/EC Article 46b – paragraph 2 – point b (b) they are accompanied by a written confirmation from the exporting third country that the standards of good manufacturing practice applicable to the plant manufacturing the exported active substance are at least equivalent to those laid down by the Community, and that the plant is subject to control and enforcement, including repeated and unannounced inspections, ensuring that those good manufacturing practices cannot be circumvented.
Amendment 192 #
Proposal for a directive – amending act Article 1 – point 4 Directive 2001/83/EC Article 46b – paragraph 2 – point b (b) they are accompanied by a written confirmation from the exporting third country that the standards of good manufacturing practice applicable to the plant manufacturing the exported active substance are at least equivalent to those laid down by the Community, and that the plant is subject to strict and transparent control and enforcement ensuring that those good manufacturing practices cannot be circumvented.
Amendment 193 #
Proposal for a directive – amending act Article 1 – point 5 Directive 2001/83/EC Article 47 – paragraph 3 The Commission shall adopt, by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c, the principles of good manufacturing and distribution practices for active substances used as starting materials and excipients referred to in point (f) of Article 46 and in Article 46b
Amendment 194 #
Proposal for a directive – amending act Article 1 – point 5 Directive 2001/83/EC Article 47 – paragraph 3 The principles of good manufacturing and distribution practices for active substances used as starting materials referred to in point (f) of Article 46 and in Article 46b shall be adopted in the form of detailed guidelines.
Amendment 195 #
Proposal for a directive – amending act Article 1 – point 5 Directive 2001/83/EC Article 47 – paragraph 3 ‘The principles of good manufacturing and distribution practices for active substances used as starting materials referred to in point (f) of Article 46 and in Article 46b shall be adopted in the form of detailed guidelines.’
Amendment 196 #
Proposal for a directive – amending act Article 1 – point 5 Directive 2001/83/EC Article 47 – paragraph 3 ‘The principles of good manufacturing practice for active substances used as starting materials referred to in point (f) of Article 46 and in Article 46b shall be adopted in the form of detailed guidelines.’ The principles by which the manufacturing authorisation holder ensures that excipients are suitable for use in manufacturing operations, carried out using risk based analyses under the principles of good manufacturing practices, shall be adopted in the form of guidelines.
Amendment 197 #
Proposal for a directive – amending act Article 1 - point 7 Directive 2001/83/EC Article 52a Importers
Amendment 198 #
Proposal for a directive – amending act Article 1 - point 7 Directive 2001/83/EC Article 52a Importers
Amendment 199 #
Proposal for a directive – amending act Article 1 - point 7 Directive 2001/83/EC Article 52b (1) Notwithstanding Article 2(1), and without prejudice to Title VII, Member States shall
Amendment 200 #
Proposal for a directive – amending act Article 1 - point 7 Directive 2001/83/EC Article 52 c (new) Article 52c The Commission shall study the possibilities for the authentication of individual dosage forms, as a method of detecting falsified medicinal products.
Amendment 201 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products
Amendment 202 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o ‘(o) safety features making is possible to ascertain identification
Amendment 203 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to
Amendment 204 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals,
Amendment 205 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o ‘o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals
Amendment 206 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, and other products that are subject to a managed distribution chain, subject to medical prescription as defined in Title VI.
Amendment 207 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o ‘(o) safety features making it possible to ascertain identification
Amendment 208 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain unique identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, subject to medical prescription as defined in Title VI.
Amendment 209 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, subject to medical prescription as defined in Title VI, where the Commission decides that there is a risk that a medicinal product will be counterfeited due to the price or past incidences.
Amendment 210 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, subject to medical prescription as defined in Title VI. This point shall apply to all generic medicines subject to medicinal prescription.
Amendment 211 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o ‘(o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, subject to medicinal prescription as defined in Title VI. 36 months at the latest after entry into force of this Directive, the traceability procedure for medicinal products should be harmonised at EU level. Hence, each medicinal product should be unequivocally identified by means of a serial number on its individual packaging.’
Amendment 212 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, subject to medical prescription as defined in Title VI. Those safety features shall be applied without discrimination through marketing channels.
Amendment 213 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o (o) safety features making it possible to ascertain identification, authenticity and traceability of medicinal products, other than radiopharmaceuticals, subject to medical prescription as defined in Title VI. Homeopathic medicinal products are exempt in accordance with Article 1(5). Where a medicinal product, such as a homeopathic medicinal product, is not subject to medical prescription, the safety features may be applied on a voluntary basis.
Amendment 214 #
Proposal for a directive – amending act Article 1 - point 8 Directive 2001/83/EC Article 54 - point o a (new) (oa) details of the product source (country, firm, production site) with a view to ensuring the traceability of the active pharmaceutical ingredient and where the active ingredient is produced outside the European Union, an indication of the country of origin on the medicinal product package.
Amendment 215 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 1 - introductory part 1. The safety features referred to in point (o) of Article 54 shall allow wholesale distributors or pharmacists
Amendment 216 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 1 – point a a) verify authenticity
Amendment 217 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 1 - point a (a) verify authenticity by assessing overt
Amendment 218 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 1 – point b (b) identify individual packs by means of a unique machine-readable serialisation code;
Amendment 219 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 1 – point b (b) identify individual packs by a single EU-wide standard;
Amendment 220 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – introductory part Amendment 221 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – introductory part Amendment 222 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – introductory part 2. The safety features referred to in point (o) of Article 54 shall not be
Amendment 223 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point a Amendment 224 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point a Amendment 225 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point a (a) The manufacturing authorisation holder
Amendment 226 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point b Amendment 227 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point b Amendment 228 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point b (b) The manufacturing authorisation holder complies with point (o) of Article 54
Amendment 229 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 – point b (b) The manufacturing authorisation holder complies with point (o) of Article 54 by replacing the safety feature with a safety feature which is equivalent as regards the possibility to ascertain identification, authenticity and
Amendment 230 #
Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point b (b) The manufacturing authorisation holder complies with point (o) of Article 54 by replacing the safety feature with a safety feature which is equivalent as regards the possibility to ascertain identification
Amendment 231 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 – point b (b) The manufacturing authorisation holder complies with point (o) of Article 54 by replacing the safety feature with a safety feature which is equivalent as regards the possibility to ascertain identification, authenticity and uninterrupted traceability of the medicinal product, and without
Amendment 232 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 – point b (b) The manufacturing authorisation holder complies with point (o) of Article 54 by replacing the safety feature with a safety feature which is equivalent as regards the possibility to ascertain identification, authenticity and uninterrupted traceability of the medicinal product, and without opening the immediate packaging as defined in Article 1(23). To this effect, the manufacturing authorisation holder shall produce a new outer carton replicating all relevant product and trademark information and subject to carrying safety features as required by Article 54(o); original cartons shall be destroyed;
Amendment 233 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2– point b (b) The manufacturing authorisation holder complies with point (o) of Article 54 by replacing the safety feature with a safety feature which is equivalent as regards the possibility to ascertain identification, authenticity and uninterrupted traceability of the medicinal product, and without opening the immediate packaging as defined in Article 1(23); To this effect, the manufacturing authorisation holder shall produce a new outer carton replicating all relevant product and trademark information and subject to carrying safety features as required by Article 54(o); original cartons shall be destroyed;
Amendment 234 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 – point b - subparagraph 1 a (new) Safety features shall be considered equivalent where they are equally efficient in identifying, authenticating, tracing and preventing tampering with medicinal product, and where they are equally technical difficult to duplicate. This paragraph shall also apply to the removal, replacement or covering up of new safety features unless the primary safety feature is a covert one and cannot be recognised.
Amendment 235 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 – point b - subparagraph 1 a (new) Safety features shall be considered equivalent where they are equally efficient in identifying, authenticating, tracing and preventing tampering with medicinal products, and where they are equally technical difficult to duplicate. This paragraph shall also apply to the removal, replacement or covering up of new safety features.
Amendment 236 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 - point b - subparagraph 1 a (new) Safety features shall be considered equivalent where they are equally efficient in identifying, authenticating, tracing and preventing tampering with medicinal products, and where they are equally technical difficult to duplicate.
Amendment 237 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point c Amendment 238 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point c Amendment 239 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a - paragraph 2 – point c (c) The
Amendment 240 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 – point c a (new) (c a) Manufacturing authorisation holders clearly indicate on the outer packaging where the original safety features have been partly or fully removed or covered up.
Amendment 241 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 - point c a (new) (c a) The safety features referred to in point (o) of Article 54 shall be applied without discrimination between distribution channels.
Amendment 242 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 2 – point c a (new) (c a) The safety features referred to in point (o) of Article 54 shall be applied without discrimination between distribution channels.
Amendment 243 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 3 Amendment 244 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 3 Amendment 245 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 3 (3) Manufacturing authorisation holders engaged in the activities referred to in paragraph (2) of Article 54a shall be liable for damages in accordance with Council Directive 85/374/EEC caused by medicinal products which are falsified in terms of their identity.
Amendment 246 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 1 The Commission shall adopt the measures necessary for the implementation of point (o) of Article 54 and of paragraphs (1) and (2) of this Article.
Amendment 247 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 1 Amendment 248 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 1 4. The Commission shall adopt the measures necessary for the implementation of point (o) of Article 54 and of paragraphs (1) and (2) of this Article. Before formulating a specific proposal, and in order to choose the option that best matches citizens' needs, the Commission shall perform an impact assessment of the costs and benefits of the anti- counterfeiting systems currently in force and seek the views of those involved in the implementation and use of such authenticating seals.
Amendment 249 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 1 Amendment 250 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 1 Amendment 251 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 1 a (new) Before formulating a specific proposal, the Commission shall perform an impact assessment of the costs and benefits of the anti-counterfeiting systems currently in force and seek the views of those involved in the implementation and use of such authenticating seals.
Amendment 252 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 2 Amendment 253 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 2 a (new) Before the Commission adopts a measure to implement point (o) of Article 54, it shall perform a public impact assessment evaluating the costs and benefits of the existing safety features and consult all parties involved in the implementation and use of such safety features.
Amendment 254 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – introductory part When adopting those measures, the Commission shall consider the risk related to pr
Amendment 255 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – introductory part When adopting those measures, the Commission shall consider the risk related to all products or all categories of products and at least all of the following:
Amendment 256 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point a Amendment 257 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point a (a) the price
Amendment 258 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point a a (new) (aa) the complexity of the supply chain;
Amendment 259 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 3 – point a a (new) (aa) the complexity of the supply chain;
Amendment 260 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point b (b) The number
Amendment 261 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point b (b) the number
Amendment 262 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point b (b) the number
Amendment 263 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point c Amendment 264 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point c Amendment 265 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point d Amendment 266 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point d Amendment 267 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point e Amendment 268 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point e Amendment 269 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 3 – point e a (new) (ea) other potential public health hazards.
Amendment 270 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 3 a (new) The safety features (other than serialisation numbering) shall be imposed through identification of one or more categories of features that must be used for particular products or categories of products. The Commission’s Pharmaceutical Committee shall define categories comprising safety features offering equivalent efficiency and effectiveness, and features from the same category will then be considered equivalent for purposes of paragraph 2(b). Manufacturing authorisation holders may select which specific feature or features to use within a category, unless the Commission specifies reasons for requiring that a particular safety feature be used.
Amendment 271 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 4 Amendment 272 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 4 On the basis of these criteria, the
Amendment 273 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 4 On the basis of these criteria, the
Amendment 274 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 4 On the basis of these criteria, the requirements referred to in point
Amendment 275 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 4 a (new) The safety features may be used voluntarily for all medicinal products irrespectively of their prescription status and it the marketing authorisation holders may employ the safety features on their products.
Amendment 276 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 a (new) 4a. By five years after the date of entry into force of the implementing measure of this Article, the Commission should submit to the European Parliament and to the Council an assessment report on the application of the safety features referred to in point (o) of Article 54 and their contribution to the reduction of the number of falsified medicines in the legal supply chain in the Union and the potential benefits of alternative technologies and the possibilities for authentication of individual dosage forms.
Amendment 277 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 a (new) 4a. For a transitional period of three years, safety features shall be regarded as equivalent if they make it equally possible to ascertain the identity, authenticity and uninterrupted traceability of the medicinal product, without its being necessary to open the immediate packaging, or they make it equally difficult to counterfeit the product. If a safety feature is removed, replaced or covered, this point should also be applicable to the new safety feature, provided that the primary safety feature is not hidden and cannot be recognised.
Amendment 278 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the
Amendment 279 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account
Amendment 280 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account
Amendment 281 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights. The safety features shall not be used to transfer data apart from the necessary data to prevent counterfeiting and data related to social security systems. Especially the commercial treatment of data, that makes it possible to connect the pharmaceuticals with the patients, the doctors or the pharmacist has to be prevented.
Amendment 282 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall comply with relevant provisions of Union law with regard to protection of personal data and shall take due account of the legitimate interests to protect information of a
Amendment 283 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights. It has to be ensured that no collection or commercial processing of data takes place that would enable a link to be made between the medicinal products provided and the corresponding patients or pharmacies.’
Amendment 284 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights.
Amendment 285 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights. It has to be ensured that no collection or commercial processing of data takes place that would enable a link to be made between the medicinal products supplied and the corresponding patients or pharmacies.’
Amendment 286 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights. Member States shall ensure that the ownership and confidentiality of data generated by the use of safety features to authenticate medical products is respected.
Amendment 287 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 a (new) The measures referred to in this paragraph shall take due account of the legitimate interests to protect information of a commercially confidential nature and of the protection of industrial and commercial property rights. Member States shall undertake to ensure that the ownership and confidentiality of the data generated by using technology to combat counterfeiting of pharmaceutical products are respected.’
Amendment 288 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 a (new) The measures referred to in this paragraph shall be updated every year on the basis of the Commission report pursuant to Article 46(h).
Amendment 289 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 a (new) Member States shall ensure that the ownership and confidentiality of the data generated by using technology to combat counterfeiting of pharmaceutical products are respected.
Amendment 290 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54 a – paragraph 4 – subparagraph 5 a (new) Member States shall ensure that both the ownership and the confidentiality of the data elicited when applying the safety features for the purpose of identifying medicinal products are respected.
Amendment 291 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 a (new) 4a. Five years from the entry into force of this Directive, the Commission shall present a report to the European Parliament and the Council concerning the implementation thereof. In this report the Commission shall assess the effectiveness of the provisions adopted further to Article 54 concerning measures to prevent falsified medicinal products entering the legal distribution chain.
Amendment 292 #
Proposal for a directive – amending act Article 1 - point 9 Directive 2001/83/EC Article 54a – paragraph 4 b (new) 4b. Any Member State may extend the scope of the safety features referred to in paragraph (o) of Article 54 to other medicinal products and to other relevant areas of national policy such as reimbursement.
Amendment 293 #
Proposal for a directive – amending act Article 1 - point 9 a (new) Directive 2001/83/EC Article 55 – paragraph 2 (9a) In Article 55, paragraph 2 is replaced by the following: 2. The following particulars at least shall appear on immediate packagings which take the form of blister packs and are placed in an outer packaging that complies with the requirements laid down in Articles 54 and 62. - the name of the medicinal product as laid down in point (a) of Article 54, - the name of the holder of the authorization for placing the product on the market, - the expiry date, - the batch number, - the INN name."
Amendment 294 #
Proposal for a directive – amending act Article 1 - point 9 a (new) Directive 2001/83/EC Article 55 – paragraph 2 (9a) In Article 55, paragraph 2 is replaced by the following: "2. The following particulars at least shall appear on immediate packagings which take the form of blister packs and are placed in an outer packaging that complies with the requirements laid down in Articles 54 and 62. - the name of the medicinal product as laid down in point (a) of Article 54, - the name of the holder of the authorization for placing the product on the market, - the expiry date, - the batch number, - the INN name."
Amendment 295 #
Proposal for a directive – amending act Article 1 – point 10 Directive 2001/83/EC Article 57 In Article 57, the fourth indent of the first paragraph is replaced by the following: ‘-
Amendment 296 #
Proposal for a directive – amending act Article 1 – point 10 a (new) Directive 2001/83/EC Article 63 – paragraph 1 Amendment 297 #
Proposal for a directive – amending act Article 1 – point 11 Directive 2001/83/EC Title VII – Heading “Wholesale distribution
Amendment 298 #
Proposal for a directive – amending act Article 1 – point 11 Directive 2001/83/EC Title VII – Heading Wholesale distribution
Amendment 299 #
Proposal for a directive – amending act Article 1 – point 11 a (new) Directive 2001/83/EC Article 76 – paragraph 3 (11a) In Article 76, paragraph 3 is replaced by the following: 3. Any distributor, not being the marketing authorisation holder, who imports a product from another Member State shall notify the marketing authorisation holder and the competent authority in the Member State to which the product will be imported of his intention to import it. In the case of products which have not been granted an authorisation pursuant to Regulation (EC) No 726/2004, the notification to the competent authority shall be without prejudice to additional procedures provided for in the legislation of that Member State, including fees payable to the competent authorities for the examination of the notification.
Amendment 300 #
Proposal for a directive – amending act Article 1 – point 11 a (new) Directive 2001/83/EC Article 76 – paragraph 3 a (new) (11a) In Article 76, the following paragraph is added: 3a. In the case of products which have been granted an authorisation pursuant to Regulation (EC) No 726/2004, the distributor shall submit the notification in accordance with paragraph 3 to the marketing authorisation holder and the Agency. The notification shall be accompanied by a fee payable to the Agency for checking that the conditions laid down in Union legislation are complied with.
Amendment 301 #
Proposal for a directive – amending act Article 1 – point 11 b (new) Directive 2001/83/EC Article 77 – paragraph 1 (11b) In Article 77, paragraph 1 is replaced by the following: ‘1. Member States shall take all appropriate measures to ensure that the wholesale distribution, trade and brokerage of medicinal products is subject to the possession of an authorization to engage in activity as a wholesaler, trader or broker in medicinal products, stating the place for which it is valid.’
Amendment 302 #
Proposal for a directive – amending act Article 1 – point 12 a (new) Directive 2001/83/EC Article 77 – paragraph 5 (12a) In Article 77, paragraph 5 is replaced by the following: 5. Checks on the persons authorized to engage in the activity of wholesaling, trading or brokering in medicinal products and the inspection of their premises, as applicable, shall be carried out under the responsibility of the Member State which granted the authorization.
Amendment 303 #
Proposal for a directive – amending act Article 1 – point 12 b (new) Directive 2001/83/EC Article 77 – paragraph 6 (12b) In Article 77, paragraph 6 is replaced by the following: 6. The Member State which granted the authorization referred to in paragraph 1 shall suspend or revoke that authorisation, after having notified the holder thereof, if the conditions of authorisation cease to be met or if the authorisation has not been used for more than three years, except in cases where the authorisation was not used on account of the time reasonably necessary to comply with the obligations under this Directive. That Member State shall forthwith inform the other Member States and the Commission thereof.
Amendment 304 #
Proposal for a directive – amending act Article 1 – point 12 b (new) Directive 2001/83/EC Article 77 – paragraph 6 (12b) In Article 77, paragraph 6 is replaced by the following: ‘6. The Member State which granted the authorization referred to in paragraph 1 shall suspend or revoke that authorization, after having notified the holder thereof, if the conditions of authorization cease to be met or if the authorisation has not been used for more than three years. That Member State shall forthwith inform the other Member States and the Commission thereof.’
Amendment 305 #
Proposal for a directive – amending act Article 1 – point 12 c (new) Directive 2001/83/EC Article 78 (12c) Article 78 is replaced by the following: Member States shall ensure that the time taken for the procedure for examining the application for the distribution, trade or brokerage authorization does not exceed 90 days from the day on which the competent authority of the Member State concerned receives the application. The competent authority may, if need be, require the applicant to supply all necessary information concerning the conditions of authorization. Where the authority exercises this option, the period laid down in the first paragraph shall be suspended until the requisite additional data have been supplied.’
Amendment 306 #
Proposal for a directive – amending act Article 1 – point 12 d (new) Directive 2001/83/EC Article 79 a (new) (12d) The following Article 79a is inserted: ‘Article 79a The Commission shall, in cooperation with the Agency and Member State authorities, lay down rules and criteria for obtaining trade and brokerage authorisations. Applicants must fulfil the following minimum requirements: (a) they must have a permanent address or contact details, so as to ensure accurate identification and location of their official place of business; (b) they must undertake to ensure that they conduct their activities only with those persons or entities that are able to fulfil their obligations under the terms of Article 80.’
Amendment 307 #
Proposal for a directive – amending act Article 1 – point 12 d (new) Directive 2001/83/EC Article 79 a (new) (12d) The following Article 79a is inserted: ‘Article 79a The Commission shall, in cooperation with the Agency and Member State authorities, lay down rules and criteria for obtaining trade and brokerage authorisations. Applicants must fulfil the following minimum requirements: (a) they must have a permanent address or contact details, so as to ensure accurate identification and location of their official place of business; (b) they must undertake to ensure that they conduct their activities only with those persons or entities that are able to fulfil their obligations under the terms of Article 80.'
Amendment 308 #
Proposal for a directive – amending act Article 1 – point 13 - point -a (new) Directive 2001/83/EC Article 80 – introductory sentence (-a) The introductory sentence is replaced by the following: ‘Holders of the authorisation for distributing, trading or brokering medicinal products must fulfil the following minimum requirements:’
Amendment 309 #
Proposal for a directive – amending act Article 1 – point 13 – point -a (new) Directive 2001/83/EC Article 80 – introductory sentence (-a) The introductory sentence is replaced by the following: ‘Holders of the authorisation for distributing, trading or brokering medicinal products must fulfil the following minimum requirements:’
Amendment 310 #
Proposal for a directive – amending act Article 1 – point 13 - point -a a (new) Directive 2001/83/EC Article 80 – point c a (new) (-a a) The following point (ca) is added: '(ca) they must randomly verify that the medicinal products they have purchased are not falsified by checking the safety feature on the outer packaging, as referred to in point (o) of Article 54;'
Amendment 311 #
Proposal for a directive – amending act Article 1 – point 13 – point -a a (new) Directive 2001/83/EC Article 80 – point c a (new) (-aa) The following point (ca) is added: (ca) they must check that the medicinal products they have purchased are not falsified by authenticating the unique identification feature on the outer packaging;
Amendment 312 #
Proposal for a directive – amending act Article 1 – point 13 – point a Directive 2001/83/EC Article 80 – point e (e) they must keep records either in the form of purchase/sales invoices or on computer, or in any other form, giving for any transaction in medicinal products received, dispatched
Amendment 313 #
Proposal for a directive – amending act Article 1 – point 13 – point a a (new) Directive 2001/83/EC Article 80 – point g (aa) Point (g) is replaced by the following: '(g) they must comply with the principles and guidelines of good distribution, trading and brokering practice for medicinal products as laid down in Article 84.'
Amendment 314 #
Proposal for a directive – amending act Article 1 – point 13 – point a a (new) Directive 2001/83/EC Article 80 – point g (aa) Point (g) is replaced by the following: ‘(g) they must comply with the principles and guidelines of good distribution practice, or principles and guidelines of good trade practices, or principles and guidelines of good brokerage practices for medicinal products as laid down in Article 84.’
Amendment 315 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 1 (i) they must inform the competent authority of products they receive, trade or broke which they identify as
Amendment 316 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 1 (i) they must inform the competent authority of products they receive, trade or broker which they identify as infringing, or they suspect of infringing, either of the following:
Amendment 317 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 2 Moreover, in cases where these
Amendment 318 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 2 Moreover, in cases where these infringements or suspected infringements relate to a falsified medicinal product, the holder of the marketing authorisation or of the trademark that has been falsified shall be informed.
Amendment 319 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 2 Moreover, in cases where these infringements or suspected infringements relate to a falsified medicinal product, the holder of the marketing authorisation or of the trademark that has been falsified shall be informed.
Amendment 320 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 2 Moreover, in cases where these infringements or suspected infringements relate to a falsified medicinal product, the holder of the marketing authorisation or of the trademark that has been falsified shall be informed.
Amendment 321 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 2 Moreover, in cases where these infringements or suspected infringements relate to a falsified medicinal product, the holder of the marketing authorisation or of the trademark that has been falsified shall
Amendment 322 #
Proposal for a directive – amending act Article 1 – point 13 – point b Directive 2001/83/EC Article 80 – point i – paragraph 2 Moreover, in cases where these infringements or suspected infringements relate to a falsified medicinal product, the holder of the marketing authorisation or of the trademark that has been falsified shall be informed
Amendment 323 #
Proposal for a directive – amending act Article 1 – point 13 – point c Directive 2001/83/EC Article 80 – subparagraph 1 a Amendment 324 #
Proposal for a directive – amending act Article 1 – point 13 – point c Directive 2001/83/EC Article 80 – subparagraph 1 a ‘For the purpose of point (b), in the case where the product is obtained from another wholesale distributor, holders of the wholesale distribution authorisation must verify compliance with good distribution practices of the supplying wholesale distributor
Amendment 325 #
Proposal for a directive – amending act Article 1 – point 13 – point c Directive 2001/83/EC Article 80 – subparagraph 1 b Where the product is obtained
Amendment 326 #
Proposal for a directive – amending act Article 1 – point 13 a (new) Directive 2001/83/EC Article 84 (13a) Article 84 is replaced by the following: ‘Article 84 The Commission shall publish guidelines on good distribution, trading and brokering practice for medicinal products. To this end, it shall consult the Committee for Proprietary Medicinal Products and the Pharmaceutical Committee established by Council Decision 75/320/EEC1. 1 OJ L 147, 9.6.1975, p. 23.’
Amendment 327 #
Proposal for a directive – amending act Article 1 – point 13 a (new) Directive 2001/83/EC Article 84 (13a) Article 84 is replaced by the following: ‘Article 84 The Commission shall publish guidelines on good distribution, trading and brokering practice for medicinal products. To this end, it shall consult the Committee for Proprietary Medicinal Products and the Pharmaceutical Committee established by Council Decision 75/320/EEC1. 1 OJ L 147, 9.6.1975, p. 23.’
Amendment 328 #
Proposal for a directive – amending act Article 1 – point 13 b (new) Directive 2001/83/EC Article 84 a (new) (13b) the following Article 84a is inserted: 'Article 84a The Commission shall publish guidelines on specific good manufacturing practices for active pharmaceutical ingredients and specific good manufacturing practices for excipients. To this end, it shall consult the Committee for Proprietary Medicinal Products established under Council Directive 75/319/EEC and the Pharmaceutical Committee established by Council Decision 75/320/EEC, taking into account the GMP equivalent systems in force such as HACCP and ISO9001/ISO22000 and the voluntary rules such as the EFfCI GMP and the IPEC PQG Guide for pharmaceutical excipients.'
Amendment 329 #
Proposal for a directive – amending act Article 1 – point 14 Directive 2001/83/EC Article 85 a (new) Article 85a Member States, in cooperation with the Commission and after consulting interested parties, shall devise an information strategy concerning the reliability of suppliers of pharmaceuticals. This strategy should take into account the various national laws regulating the supply of pharmaceuticals and the risks linked to certain methods of supply of pharmaceuticals, such as illegal internet channels.
Amendment 330 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Title VII a (new) – Article 85 c (new) Amendment 331 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Title VII a (new) – Article 85 c (new) (14a) The following Title VII a and Article 85c are inserted after Article 85b: 'TITLE VII a INTERNET SALES Article 85c 1. The Commission shall adopt a EU logo for the front page of the websites of all legitimate mail-order pharmacies ensuring the general public that the respective website offering to sell medicinal products is compliant with EU legislation and is connected to a registered pharmacy. The logo shall be linked to a central website at Member State level, to be established by the Member State, that allows the visitor to check the authenticity of the logo and provides detailed information on the legality of the respective mail-order pharmacy, points of contact for further information and complaints as well as further advice on the identification of a legitimate mail- order pharmacy, e.g. by identifying the chief pharmacist. Legitimate mail-order pharmacies that are legally based in the Union and operate in the internal market must be listed in a European database to which the central website at Member State level shall be linked. Those measures shall be adopted by the Commission by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c. 2. Member States shall take the appropriate measures, including punitive measures, to ensure that all legitimate mail-order pharmacies within their territory display the EU logo referred to in paragraph 1 and to prevent illegal websites selling medicinal products from using the logo and linking to the central website referred to in paragraph 1.'
Amendment 332 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Title VII a (new) – Article 85 c (new) 14a) The following Title VIIa and Article 85c are inserted after Article 85b: 'TITLE VIIa INTERNET SALES Article 85c 1. The Commission shall, by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c, adopt an EU logo for the front page of internet pharmacy sites, helping the public to identify whether a website offering to sell medicinal products is connected to a registered pharmacy. The logo shall be linked to a central website at Member State level, to be established by the Member State, that allows the visitor to check the authenticity of the logo and that provides background information on the risks related to buying medicinal products on the internet. 2. Member States shall take the appropriate measures to ensure that all registered pharmacy internet sites linked to pharmacies within their territory display the EU logo referred to in paragraph 1 and to prevent non-registered pharmacy internet sites from using the logo and linking to the central website referred to in paragraph 1.'
Amendment 333 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Title VII a (new) – Article 85 c (new) (14a) The following Title VIIa and Article 85c are inserted after Article 85b: 'TITLE VIIa INTERNET SALES Article 85c 1. The Commission shall adopt an EU logo for the front page of internet pharmacy sites, helping the public to identify whether a website offering to sell medicinal products is connected to a registered pharmacy. The logo shall be tamper-proof and incorporate features that help prevent it from being copied and it shall also be linked to a secure central website at Member State level, to be established by the Member State, that allows the visitor to check the authenticity of the logo and that provides background information on the risks related to buying medicinal products on the internet. Those measures shall be adopted by the Commission by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c. 2. Member States shall take the appropriate measures to ensure that all registered pharmacy internet sites linked to pharmacies within their territory display the EU logo referred to in paragraph 1 and to prevent non-registered pharmacy internet sites from using the logo and linking to the central website referred to in paragraph 1.'
Amendment 334 #
Proposal for a directive – amending act Article 1 – point 14 a (new) Directive 2001/83/EC Title VII a (new) – Article 85 c (new) Amendment 335 #
Proposal for a directive – amending act Article 1 – point 14 b (new) Directive 2001/83/EC Article 85 d (new) Amendment 336 #
Proposal for a directive – amending act Article 1 – point 14 b (new) Directive 2001/83/EC Article 85 d (new) (14b) The following Article 85d is inserted: 'Article 85d 1. The Commission shall, by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c, adopt measures to increase awareness among the general public on the risks related to purchasing medicinal products on the internet, which may include: - warnings appearing on top of the internet page in search engines in the event of a search for medicinal products on the internet; - general information campaigns, in cooperation with the Member States; - easily accessible lists of accredited e- pharmacies'
Amendment 337 #
Proposal for a directive – amending act Article 1 – point 14 b (new) Directive 2001/83/EC Article 85 d (new) (14b) The following Article 85d is inserted: 'Article 85d 1. The Commission shall adopt measures to increase awareness among the general public on the risks related to purchasing medicinal products on the internet, which may include: - general information campaigns, in cooperation with the Member States; - easily accessible lists of accredited e- pharmacies Those measures shall be adopted by the Commission by means of delegated acts in accordance with Article 121a and subject to the conditions of Articles 121b and 121c.'
Amendment 338 #
Proposal for a directive – amending act Article 1 – point 14 c (new) Directive 2001/83/EC Article 85 e (new) (14c) The following Article 85e is inserted: 'Article 85e Member States shall ensure that all legitimate mail-order pharmacies operating in the internal market adhere to professional standards and guidance for internet pharmacy services, including a specific code of ethics. All mail-order pharmacies are obliged to clearly display the code of conduct on their websites and display contact details for complaints. Member States shall ensure that the internet is continuously monitored by a designated body with regards to the selling of medicinal products and shall take legal actions, including punitive measures, in the event of non-compliance with this Directive.'
Amendment 339 #
Proposal for a directive – amending act Article 1 – point 14 d (new) Directive 2001/83/EC Article 85 f (new) (14d) The following Article 85f is inserted: 'Article 85f Nothing in this Directive shall affect the right of Member States to restrict or prohibit the sale of prescription medicines through the internet.'
Amendment 340 #
Proposal for a directive – amending act Article 1 – point 14 e (new) Directive 2001/83/EC Article 88a a (new) (14e) The following Article is inserted: 'Article 88aa Member States, in cooperation with the Commission and after consultation with representatives of stakeholders, shall devise an information strategy relating to the safety of consignments of medicinal products. The strategy shall take account of the various national legal provisions concerning the supply of medicinal products and the risks associated with certain types of supply of medicinal products and with illegal trading on the internet.'
Amendment 341 #
Proposal for a directive – amending act Article 1 – point 14 e (new) Directive 2001/83/EC Article 88a a (new) (14e) The following Article 88a a is inserted: 'Article 88aa Member States with the collaboration of the Commission and following consultation with stakeholders should develop an information strategy regarding the reliability of medicinal products suppliers. The strategy shall take into account the different national legislation regulating the supply of medicinal products as well as the risks of certain ways of supplying medicines, such as through illegal internet traders.
Amendment 342 #
Proposal for a directive – amending act Article 1 – point 15 – point -a (new) Directive 2001/83/EC Article 111 – paragraph 1 (-a) Paragraph 1 is replaced by the following: '1. The competent authorities of the Member State concerned shall, under the Agency's coordination, ensure by means of repeated, and where necessary unannounced, inspections, that the legal requirements governing medicinal products are complied with, and shall, where appropriate, commission an official medicinal product test laboratory, or another laboratory designated for that purpose, to carry out sampling tests. Such inspections shall be carried out by officials representing the competent authority who shall be empowered to: (a) inspect manufacturing or commercial establishments and any laboratories entrusted by the holder of the manufacturing authorization with the task of carrying out checks pursuant to Article 20; (b) take samples; (c) examine any documents which relate to the object of the inspection, subject to the provisions in force in the Member States on 21 May 1975, and which place restrictions on these powers with regard to the descriptions of the method of preparation.'
Amendment 343 #
Proposal for a directive – amending act Article 1 – point 15 – point a a (new) Directive 2001/83/EC Article 111 – paragraph 1 – subparagraph 2 (aa) In Article 111(1), subparagraph 2 is replaced by the following: '2. The competent authorities shall carry out repeated, and where necessary unannounced, inspections of the premises of producers, distributors or importers of active ingredients used as starting materials, the premises of manufacturing authorisation holders, the premises of medicinal product traders and brokers or the premises of excipient producers, importers and distributors where there are sound grounds for suspecting, on the basis of information available to the authorities or of previous cases, that legal obligations or the guidelines are not being complied with. Such inspections may also be carried out at the request of a Member State, the Commission or the Agency.'
Amendment 344 #
Proposal for a directive – amending act Article 1 – point 15 – point a a (new) Directive 2001/83/EC Article 111 – paragraph 1 – subparagraph 2 (aa) Article 111(1), subparagraph 2 is replaced by the following: The competent authority shall also carry out unannounced inspections at the premises of manufacturers, distributors or importers of active substances used as starting materials, at the premises of marketing authorisation holders and at the premises of manufacturers or importers or distributors of excipients, whenever it considers that there are grounds for suspecting non-compliance with the principles and guidelines of good manufacturing practice referred to in Article 47. These inspections may also be carried out at the request of a Member State, the Commission or the Agency. The competent authority shall also carry out unannounced inspections at the premises of manufacturers of active substances used as starting materials and of excipients based in third countries.
Amendment 345 #
Proposal for a directive – amending act Article 1 – point 15 – point a a (new) Directive 2001/83/EC Article 111 – paragraph 1 – subparagraph 2 (aa) In Article 111(1), subparagraph 2 is replaced by the following: The competent authority shall also carry out routine or unannounced inspections at the premises of manufacturers, distributors or importers of active substances used as starting materials, at the premises of marketing authorisation holders and at the premises of manufacturers or importers or distributors of excipients, whenever it considers that there are grounds for suspecting non-compliance with the principles and guidelines of good manufacturing practice referred to in Article 47. These inspections shall also be carried out if so requested by a Member State, the Commission or the Agency. The competent authority shall also carry out unannounced inspections at the premises of manufacturers of active substances used as starting materials and of excipients based in third countries.
Amendment 346 #
Proposal for a directive – amending act Article 1 – point 15 - point a a (new) Directive 2001/83/EC Article 111 – paragraph 1 – subparagraph 2 aa) The second subparagraph of paragraph 1 is replaced by the following: The competent authority shall have a supervisory system responsible for: - regular inspections in the Union of the premises of the manufacturers and importers of active substances employed as starting materials, and - the effective follow-up of said inspections. The competent authority shall be able to inspect the premises of manufacturers or importers of excipients whenever it considers that there are grounds for suspecting non-compliance with the law or the guidelines on good manufacturing practice referred to in Article 47. Inspections may also be carried out on the premises of marketing authorisation holders, distributors and brokers in the medicinal products trade. Inspections in the Community and in non-EU countries may be requested by a Member State, the Commission or the Agency.
Amendment 347 #
Proposal for a directive – amending act Article 1 – point 15 – point b Directive 2001/83/EC Article 111 – paragraph 3 3. After every inspection as referred to in paragraph 1, the competent authority shall report on whether the manufacturer, importer,
Amendment 348 #
Proposal for a directive – amending act Article 1 – point 15 – point c Directive 2001/83/EC Article 111 – paragraph 5 – subparagraph 1 5. Within 90 days of an inspection as referred to in paragraph 1, a certificate of good manufacturing practice
Amendment 349 #
Proposal for a directive – amending act Article 1 – point 15 – point c Directive 2001/83/EC Article 111 – paragraph 6 6. Member States shall enter the certificates of good manufacturing practice
Amendment 350 #
Proposal for a directive – amending act Article 1 – point 15 – point c Directive 2001/83/EC Article 111 – paragraph 6 (6) Member States shall enter the certificates of good manufacturing practice
Amendment 351 #
Proposal for a directive – amending act Article 1 – point 15 – point c Directive 2001/83/EC Article 111 – paragraph 7 7. If the outcome of the inspection as referred to in paragraph 1 is that the person does not comply with the principles and guidelines of good manufacturing practices
Amendment 352 #
Proposal for a directive – amending act Article 1 – point 16 Directive 2001/83/EC Article 111a The Commission shall adopt detailed guidelines laying down the principles for inspections referred to in Article 111 and, in particular, the Union or national bodies responsible for carrying out inspections.
Amendment 353 #
Proposal for a directive – amending act Article 1 – point 16 Directive 2001/83/EC Article 111b - paragraph 1 - introductory part Amendment 354 #
Proposal for a directive – amending act Article 1 – point 16 Directive 2001/83/EC Article 111b – paragraph 1 – introductory part 1. The Commission shall, following a request from a third country and the satisfactory conclusion of the inspection by the body responsible pursuant to Article 111a, list that country by way of a Decision if its regulatory framework for active substances exported to the Community and the respective control and enforcement ensure a protection of public health equivalent to that in the Community. Particular account shall be taken of:
Amendment 355 #
Proposal for a directive – amending act Article 1 – point 16 Directive 2001/83/EC Article 111b – paragraph 1 – point b (b) the regularity of repeated and unannounced inspections of good manufacturing practices;
Amendment 356 #
Proposal for a directive – amending act Article 1 – point 16 Directive 2001/83/EC Article 111b - paragraph 2 (2 ) The Commission
Amendment 357 #
Proposal for a directive – amending act Article 1 – point 16 Directive 2001/83/EC Article 111b – paragraph 3 3. The Commission, in cooperation with the Agency and competent authorities of the Member States, shall verify regularly whether the conditions set out in paragraph 1 are fulfilled. The first verification shall
Amendment 358 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118a Amendment 359 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118a The competent authorities shall issue the accreditation referred to in Articles 46(f) and 80(b) if the applicant can demonstrate that he is competent to carry out verification of compliance with good manufacturing practices or, in the case of wholesale distributors, good distribution practices or, in the case of traders, good trading practices or, in the case of brokers, good brokering practices.
Amendment 360 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118b 1. Member States, in applying this Directive, shall take the necessary measures to ensure cooperation between competent authorities for medicinal products and customs authorities.
Amendment 361 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118b a (new) Article 118ba The penalties referred to in Article 118b should be equivalent to those typically applied for illegal acts related to narcotics and should be equivalent in all Member States in accordance with the Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health.
Amendment 362 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118b b (new) Article 118bb The Commission shall establish a network between the Commission, EMEA and the competent authorities in the Member States to ensure the exchange of information on the measures taken to combat the falsification of medicinal products, including on the penalties systems in place. This network shall aim at defining best practices and shall contribute to increased cooperation in the area of prevention and enforcement. The Commission, EMEA and the competent authorities in the Member States shall report to this network on the actions they have undertaken.
Amendment 363 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118c a (new) Amendment 364 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118c a (new) Article 118c a The Commission, working with the Member States, shall support the drafting, under the auspices of the United Nations, of an international convention on the combating of the falsification of medicinal products, with a view to ensuring that stiffer penalties are imposed on those guilty of such falsification.
Amendment 365 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118c b (new) Article 118c b The Commission, working closely with the Member States, shall take concerted measures with the competent authorities of third States which have transit areas in which medicinal products are stored. The Commission shall take the necessary measures to ensure that seizures of suspect products do not serve to hamper trade in legal generic medicinal products. In the context of international cooperation, the Commission shall authorise the impounding of suspect products so that the necessary checks can be carried out.
Amendment 366 #
Proposal for a directive – amending act Article 1 – point 17 Directive 2001/83/EC Article 118c c (new) Article 118c c The Commission, working closely with the Member States, shall organise an information campaign aimed at the general public on the dangers of counterfeit medicinal products, including the Internet-related risks.
Amendment 367 #
Proposal for a directive – amending act Article 1 – point 17 a (new) Directive 2001/83/EC Article 121a (17a) The following Article 121a is inserted: Article 121a Exercise of the delegation (1)The powers to adopt the delegated acts referred to in Article 52b shall be conferred on the Commission for an indeterminate period of time. (2) As soon as it adopts a delegated act, the Commission shall notify it simultaneously to the European Parliament and to the Council. (3) The powers to adopt delegated acts are conferred on the Commission subject to the conditions laid down in Articles 121b and 121c.
Amendment 368 #
Proposal for a directive – amending act Article 1 – point 17 a (new) Directive 2001/83/EC Article 121b (17a) The following Article 121b is inserted: Article 121b Revocation of the delegation 1. The delegation of power referred to in Article 52b may be revoked by the European Parliament or by the Council. 2. The institution which has commenced an internal procedure for deciding whether to revoke the delegation of power shall endeavour to inform the other institution and the Commission within a reasonable time before the final decision is taken, indicating the delegated powers which could be subject to revocation and possible reasons for a revocation. 3. The decision of revocation shall put an end to the delegation of the powers specified in that decision. It shall take effect immediately or at a later date specified therein. It shall not affect the validity of the delegated acts already in force. It shall be published in the Official Journal of the European Union.
Amendment 369 #
Proposal for a directive – amending act Article 1 – point 17 a (new) Directive 2001/83/EC Article 121c (17a) The following Article 121c is inserted: Article 121c Objections to delegated acts 1. The European Parliament or the Council may object to a delegated act within a period of two months from the date of notification. At the initiative of the European Parliament or the Council this period shall be extended by two months. 2. If neither the European Parliament nor the Council has objected to the delegated act, it shall be published in the Official Journal of the European Union and enter into force at the date stated therein. 3. If the European Parliament or the Council objects to the adopted delegated act, it shall not enter into force. The institution which objects shall state the reasons for objecting to the delegated act.
Amendment 370 #
Proposal for a directive – amending act Article 2 – paragraph 2 a (new) 2a. This Directive shall not in any way alter the right of Member States to restrict or prohibit the sale of prescription pharmaceuticals over the internet.
Amendment 371 #
Proposal for a directive – amending act Article 2 – paragraph 2 a (new) 2a. Not later than two years after the date of entry into force of this Directive, the internet pharmacy safety features included in this legislation shall be in place. The Commission shall also submit to the European Parliament and the Council an assessment report on the application of the safety features, including any related to internet pharmacies, referred to in point (o) of Article 54 of Directive 2001/83/EC and their estimated contribution to the reduction of the number of falsified medicines in the legal supply chain in Europe. The report should include an assessment of the safety features of other categories of medicines and of internet pharmacies, including medicinal products not subject to medical prescription as defined in Title VI of Directive 2001/83/EC. If appropriate the Commission shall present the proposals to the European Parliament and Council within a year of the publication of this report.
Amendment 372 #
Proposal for a directive – amending act Article 2 – paragraph 2 a (new) Amendment 373 #
Proposal for a directive – amending act Article 2 – paragraph 2 a (new) 2a. Nothing in this Directive shall affect the right of Member States to restrict or prohibit the sale of prescription medicines through the internet.
Amendment 374 #
Proposal for a directive – amending act Article 2 – paragraph 2 a (new) 2a. In accordance with the principle of subsidiarity enshrined in Article 5 of the Treaty on European Union, this Directive shall not in any way alter the right of Member States to impose restrictions on the sale of prescription pharmaceuticals over the internet.
Amendment 51 #
Proposal for a directive – amending act Citation 1 Having regard to the Treaty
Amendment 52 #
Proposal for a directive – amending act Recital 3 a (new) Amendment 53 #
Proposal for a directive – amending act Recital 3 a (new) (3a) In the light of this Directive the Commission should submit every year to the European Parliament and to the Council a statistical report with reliable and accurate data on the current situation, trends and developments in counterfeiting/falsified medicines, including details of where, how and by whom the counterfeit products were detected, the country from which they came, and the ‘counterfeit’ element itself (identity, source and/or ingredient/components) in the Member States.
Amendment 54 #
Proposal for a directive – amending act Recital 3 a (new) (3a) The Commission should submit every year to the European Parliament and to the Council a report on the current situation and trends in the falsification of medicinal products, and update the measures on the application of the safety features accordingly.
Amendment 55 #
Proposal for a directive – amending act Recital 3 a (new) (3a) Within three years of the entry into force of this Directive, the Commission should present to the European Parliament and the Council an assessment report providing detailed data on the extent and sources of counterfeit medicinal products in the legal supply chain in the Union.
Amendment 56 #
Proposal for a directive – amending act Recital 4 a (new) (4a) This Directive is to apply without prejudice to Directive 95/46/EC and should retain clear and effective safeguards whenever personal data is processed.
Amendment 57 #
Proposal for a directive – amending act Recital 4 a (new) (4a) The European Union should support the drafting of an international agreement stepping up the penalties for falsifying medicinal product, and of an additional protocol to the Palermo Convention against Transnational Organised Crime.
Amendment 58 #
Proposal for a directive – amending act Recital 4 a (new) (4a) It is well known that the internet represents one of the main routes for falsified medicinal products to enter the European market. In view of the difficulty of pinpointing the actual physical address of internet sites and, therefore, of granting them certification of authenticity with complete certainty and of verifying the quality, safety and efficacy of the pharmaceutical, the internet sale of all types of medicinal product should be prohibited, unless they have been authorised under national legislation in force on the date of entry into force of this Directive.
Amendment 59 #
Proposal for a directive – amending act Recital 4 a (new) (4a) A legitimate mail order pharmacy should be connected to a legally registered pharmacy, thereby ensuring that a legitimate mail order pharmacy must comply with all legal requirements for any pharmacy establishment in the Member State where it is legally based. The identification of the chief pharmacist should be a legal requirement for all legitimate mail order pharmacies. A mail order pharmacy can only dispense an ordered prescription medication if the original prescription has been obtained by the respective mail order pharmacy in advance. Member States should ensure that all mail order provision for pharmaceutical products is continuously regulated by designated national agencies.
Amendment 60 #
Proposal for a directive – amending act Recital 4 b (new) (4b) European citizens should be made aware of the health risks associated with ordering products from illegal websites. The Commission, in co-operation with the Member States, should adopt measures to increase awareness among the general public of the risks associated with purchasing medicinal products on the internet from any websites other than legitimate mail order pharmacies. Public awareness campaigns should inform citizens about how to identify legitimate mail order pharmacies and the risks related to buying from illegal websites.
Amendment 61 #
Proposal for a directive – amending act Recital 4 c (new) (4c) It is useful to introduce a definition of the concept of ‘falsified medicinal product’ in order to distinguish such products from legal but unauthorised medicinal products. Furthermore, authorised or otherwise legitimate products with quality defects and medicinal products that due to mistakes in the manufacturing or subsequent handling do not comply with the requirement of Good Manufacturing Practices or Good Distribution Practices should not be confused with falsified medicines.
Amendment 62 #
Proposal for a directive – amending act Recital 5 (5) Today’s distribution network for medicinal products is increasingly complex and involves many players which are not necessarily wholesale distributors as defined in Directive 2001/83/EC. In order to ensure reliability in the distribution chain, pharmaceutical legislation should address all actors in the distribution chain: this includes not only distributors who procure, hold, store and supply products, but also persons who are involved in transactions without handling the products, such as traders or brokers. They should be submitted to proportionate rules in order to exclude, by all practical means, the possibility that medicinal products which are falsified in relation to their identity, history or source to enter the
Amendment 63 #
Proposal for a directive – amending act Recital 6 a (new) (6a) Counterfeit medicinal products are often found to have been supplied in response to orders placed over the Internet. In accordance with the provisions of the TFEU, particularly Article 168 thereof, Member States are responsible for regulating the marketing of medicinal products at the last level of trade, particularly in pharmacies. This also includes regulating the marketing of medicinal products by mail order and over the Internet. The case law of the Court of Justice permits Member States to impose an absolute ban on the supply of prescription medicines by mail order, in accordance with the wide margin of discretion which they enjoy on account of the dangers associated with this method of marketing.
Amendment 64 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level.
Amendment 65 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for
Amendment 66 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the unique identification, authentication and traceability of
Amendment 67 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of
Amendment 68 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of
Amendment 69 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of
Amendment 70 #
Proposal for a directive – amending act Recital 7 7. In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription and over-the-counter medicinal products should be established at Community level. When introducing obligatory safety features for prescription and over-the-counter medicinal products, due account should be taken of the particularities of certain products or categories of products, such as generic medicines. This includes the risk of falsifications in view of their price and past incidences in the Community and abroad, as well as the consequences of falsifications for public health in view of the specific characteristics of the products concerned or of the severity of the conditions intended to be treated.
Amendment 71 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features or any other technical measure designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing obligatory safety features for prescription medicinal products, due account should be taken of the particularities of certain products or categories of products, such as generic medicines and well-established use products. This includes the risk of falsifications in view of their price and past incidences in the Community and abroad, as well as the consequences of falsifications for public health in view of the specific characteristics of the products concerned or of the severity of the conditions intended to be treated.
Amendment 72 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing obligatory safety features for prescription medicinal products, due account should be taken of the particularities of certain products or categories of products, such as generic medicines and those products that are subject to a managed distribution chain. This includes the risk of falsifications in view of their price and past incidences in the Community and abroad, as well as the consequences of falsifications for public health in view of the specific characteristics of the products concerned or of the severity of the conditions intended to be treated.
Amendment 73 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification
Amendment 74 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing obligatory safety features for prescription medicinal products, due account should be taken of the particularities of certain products or categories of products
Amendment 75 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk
Amendment 76 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing
Amendment 77 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, mandatory safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing obligatory safety features for prescription medicinal products, due account should be taken of the particularities of certain products or categories of products, such as generic medicines and excipients. This includes the risk of falsifications in view of their price and past incidences in the Community and abroad, as well as the consequences of falsifications for public health in view of the specific characteristics of the products concerned or of the severity of the conditions intended to be treated. No later than five years after the date of entry into force of this Directive, the Commission should submit to the European Parliament and to the Council an assessment report on the application of the safety features referred to in point (o) of Article 54 of Directive 2001/83/EC and their estimated contribution to the reduction of the number of falsified medicinal products in the legal supply chain in Europe. No later than 18 months after the date of entry into force of this Directive, the Commission should submit an assessment report on the safety features of over-the-counter medicinal products in accordance with Title VI of Directive 2001/83/ΕC.
Amendment 78 #
Proposal for a directive – amending act Recital 7 (7) In order to take account of new risk profiles, while at the same time ensuring the functioning of the internal market for medicinal products, safety features designed to ensure the identification, authentication and traceability of prescription medicinal products should be established at Community level. When introducing obligatory safety features for prescription medicinal products, due account should be taken of the particularities of certain products or categories of products, such as generic medicines and homeopathic medicines. This includes the risk of falsifications in view of their price and past incidences in the Community and abroad, as well as the consequences of falsifications for public health in view of the specific characteristics of the products concerned or of the severity of the conditions intended to be treated. No later than five years after the date of entry into force of this Directive, the Commission should submit to the European Parliament and to the Council an assessment report on the application of the safety features referred to in point (o) of Article 54 of Directive 2001/83/EC and their estimated contribution to the reduction of the number of falsified medicines in the legal supply chain in Europe. The report should include an assessment of the safety features of other categories of medicines, including medicinal products not subject to medical prescription as defined in Title VI of Directive 2001/83/EC.
Amendment 79 #
Proposal for a directive – amending act Recital 7 a (new) Amendment 80 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Safety features will be grouped so as to reflect the particularities of certain products or categories of products. They will be considered equivalent when they offer the same or a higher level of efficiency for ascertaining identification, authentication, traceability and absence of tampering, as well as the same level of technical difficulty for duplication. When removing, replacing or covering the safety feature, this point should also be applicable to the new safety feature.
Amendment 81 #
Proposal for a directive – amending act Recital 7 a (new) (7a) When removing, replacing or covering the safety feature, the new safety features will be considered equivalent to the original safety features when they offer the same level of efficiency for ascertaining identification, authentication, traceability and absence of tampering, as well as the same level of technical difficulty for duplication.
Amendment 82 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Safety features should be grouped so as to reflect the particularities of certain products or categories of products. They should be considered equivalent when they offer the same level of efficiency for ascertaining unique identification, authentication, traceability and absence of tampering, as well as the same level of technical difficulty for duplication. When removing, replacing or covering the safety feature an equivalent safety feature should be replaced.
Amendment 83 #
Proposal for a directive – amending act Recital 7 a (new) (7a). Over-the counter (OTC) medicinal products should be the subject of regular risk analysis study carried out by national authorities. Depending on the results of this risk analysis study, OTC medicinal products may be integrated into the scope of Directive 2001/83/EC. For that purpose, the marketing authorisation holders have the right, as soon as this Directive has entered into force, to submit their OTC medicinal products to the provisions included in this Directive.
Amendment 84 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, in consultation with stakeholders, should be free to determine the particular aspects of technologies for combating counterfeiting of pharmaceuticals which they consider most appropriate for their pharmaceutical distribution systems, taking account of the authentication seal adopted by this Directive.
Amendment 85 #
Proposal for a directive – amending act Recital 7 a (new) (7a) The use of technologies that allow the authentication and tracing of medicinal products at the level of individual dosage forms (e.g. the capsule, tablet or tamper-evident immediate packaging of liquids) can also be very valuable in terms of allowing better monitoring of products on the market.
Amendment 86 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, working together with stakeholders, should be free to determine the particular aspects of medicines authentication which they consider most appropriate for their medicine distribution system, taking into account the safety features adopted pursuant to this Directive.
Amendment 87 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, working together with stakeholders, should be free to determine the particular aspects of medicines authentication which they consider most appropriate for their medicine distribution system, taking into account the safety features adopted pursuant to this Directive.
Amendment 88 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, in cooperation with stakeholders, should be permitted to regulate the particular aspects of authentication of medicines in the way in which they consider most appropriate for their market in medicinal products, taking account of the safety features established in accordance with this Directive.
Amendment 89 #
Proposal for a directive – amending act Recital 7 a (new) (7a) Member States, together with stakeholders, should be free to determine the particular aspects of technologies for combating counterfeiting of pharmaceuticals which they consider most appropriate for their pharmaceutical distribution systems, taking account of the authentication seal adopted by this Directive.
Amendment 90 #
Proposal for a directive – amending act Recital 8 (8) Any actor in the supply chain who packages medicinal products has to be a holder of a manufacturing authorization. In order for the safety features to be effective, the manufacturing authorization holder should
Amendment 91 #
Proposal for a directive – amending act Recital 8 (8) Any actor in the supply chain who labels and packages medicinal products, or makes changes to the labelling or packaging, has to be a holder of a manufacturing authorization. In order for the safety features to be effective, the manufacturing authorization holder should only be permitted to remove, replace or cover these features under strict conditions.
Amendment 92 #
Proposal for a directive – amending act Recital 8 (8) Any actor in the supply chain who
Amendment 93 #
Proposal for a directive – amending act Recital 9 (9) These manufacturing authorisation holders
Amendment 94 #
Proposal for a directive – amending act Recital 11 a (new) (11a) The European public should be made aware of the risks run when purchasing pharmaceuticals through illegal channels. In particular, information campaigns should be promoted at both national and European level. The Commission, in conjunction with the Member States, should adopt effective measures to improve public awareness of the risks arising from purchases of pharmaceuticals over the internet.
Amendment 95 #
Proposal for a directive – amending act Recital 11 a (new) Amendment 96 #
Proposal for a directive – amending act Recital 11 a (new) (11a) European citizens should be made aware of the risks of purchasing medicinal products from illegal suppliers. An information campaign should be organised by the Member States and at EU level. The Commission and Member States should adopt measures to make the public aware of the risks of purchasing medicinal products over the internet.
Amendment 97 #
Proposal for a directive – amending act Recital 11 a (new) (11a) European citizens should have their attention drawn to the risks which arise when medicinal products are ordered from illegal suppliers. In particular, public information measures should be promoted in the Member States and throughout Europe. The Commission and Member States should adopt measures to increase awareness among the general public of the risks related to purchasing medicinal products on the Internet.
Amendment 98 #
Proposal for a directive – amending act Recital 11 a (new) (11a) European citizens should be made aware of the risks of ordering medicinal products from illegal suppliers. In particular, awareness campaigns should be promoted at Member States and EU level. The Commission together with the Member States should adopt measures to increase awareness among the general public of the risks related to purchasing medicinal products on the internet.
Amendment 99 #
Proposal for a directive – amending act Recital 11 a (new) (11a) The Commission and the Member States should adopt measures such as awareness campaigns to inform the public more fully of the risks of purchasing pharmaceutical products online.
source: PE-439.406
|
History
(these mark the time of scraping, not the official date of the change)
docs/0 |
|
docs/10 |
|
docs/12/docs/0/url |
/oeil/spdoc.do?i=18346&j=0&l=en
|
events/0 |
|
events/0 |
|
events/13/docs/1/url |
Old
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2011:174:SOM:EN:HTMLNew
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2011:174:TOC |
links/National parliaments/url |
Old
http://www.ipex.eu/IPEXL-WEB/dossier/dossier.do?code=COD&year=2008&number=0261&appLng=ENNew
https://ipexl.europarl.europa.eu/IPEXL-WEB/dossier/code=COD&year=2008&number=0261&appLng=EN |
committees/0/rapporteur |
|
docs/1/docs/0/url |
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2008/2675/COM_SEC(2008)2675_EN.pdfNew
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2675/COM_SEC(2008)2675_EN.pdf |
docs/2/docs/0/url |
Old
https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:1191)(documentyear:2009)(documentlanguage:EN)New
https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:1191)(documentyear:2009)(documentlanguage:EN) |
docs/3/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE430.883New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE430.883 |
docs/4/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.406New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE439.406 |
docs/5/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.407New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE439.407 |
docs/6/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.409New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE439.409 |
docs/7/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.860New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE439.860 |
docs/8/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE430.741&secondRef=02New
https://www.europarl.europa.eu/doceo/document/ITRE-AD-430741_EN.html |
docs/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE438.139&secondRef=03New
https://www.europarl.europa.eu/doceo/document/IMCO-AD-438139_EN.html |
docs/11/docs/0/url |
Old
http://www.europarl.europa.eu/doceo/document/A-7-2010-0148_EN.htmlNew
https://www.europarl.europa.eu/doceo/document/A-7-2010-0148_EN.html |
docs/12/docs/0/url |
/oeil/spdoc.do?i=18346&j=0&l=en
|
events/0/docs/0/url |
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0668/COM_COM(2008)0668_EN.pdfNew
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2008/0668/COM_COM(2008)0668_EN.pdf |
events/1/type |
Old
Committee referral announced in Parliament, 1st reading/single readingNew
Committee referral announced in Parliament, 1st reading |
events/2/type |
Old
Committee referral announced in Parliament, 1st reading/single readingNew
Committee referral announced in Parliament, 1st reading |
events/4/type |
Old
Vote in committee, 1st reading/single readingNew
Vote in committee, 1st reading |
events/5 |
|
events/5 |
|
events/7/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20110215&type=CRENew
https://www.europarl.europa.eu/doceo/document/EN&reference=20110215&type=CRE |
events/9 |
|
events/9 |
|
procedure/Modified legal basis |
Rules of Procedure EP 150
|
procedure/Other legal basis |
Rules of Procedure EP 159
|
committees/0 |
|
committees/0 |
|
committees/1/date |
|
committees/2 |
|
committees/2 |
|
committees/3 |
|
committees/3 |
|
committees/4/date |
|
committees/5/date |
|
docs/11/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-148&language=ENNew
http://www.europarl.europa.eu/doceo/document/A-7-2010-0148_EN.html |
docs/12/body |
EC
|
events/5/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-148&language=ENNew
http://www.europarl.europa.eu/doceo/document/A-7-2010-0148_EN.html |
events/9/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2011-56New
http://www.europarl.europa.eu/doceo/document/TA-7-2011-0056_EN.html |
activities |
|
commission |
|
committees/0 |
|
committees/0 |
|
committees/1 |
|
committees/1 |
|
committees/2 |
|
committees/2 |
|
committees/3 |
|
committees/3 |
|
committees/4 |
|
committees/4 |
|
committees/5 |
|
committees/5 |
|
council |
|
docs |
|
events |
|
other |
|
procedure/Modified legal basis |
Old
Rules of Procedure of the European Parliament EP 150New
Rules of Procedure EP 150 |
procedure/dossier_of_the_committee |
Old
ENVI/7/00148New
|
procedure/final/url |
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32011L0062New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32011L0062 |
procedure/instrument |
Old
DirectiveNew
|
procedure/subject |
Old
New
|
procedure/summary |
|
procedure/title |
Old
Medicinal products for human use: prevention of the entry into the legal supply chain of falsified medicinal productsNew
Medicinal products for human use: prevention of the entry into the legal supply chain of falsified medicinal products |
activities/0/docs/0/url |
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0668/COM_COM(2008)0668_EN.pdfNew
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2008/0668/COM_COM(2008)0668_EN.pdf |
activities/12/docs/1/url |
Old
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2011:174:TOCNew
http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2011:174:SOM:EN:HTML |
links/European Commission/title |
Old
PreLexNew
EUR-Lex |
activities |
|
committees |
|
links |
|
other |
|
procedure |
|